[
  {
    "compound": "Medical cannabis/cannabinoids",
    "condition": "ALZHEIMERS",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:ALZHEIMERS_GUIDELINE_001",
    "participants": "Evidence-based guideline",
    "year": 2019,
    "notes": "Canadian Guidelines for Cannabis in Older Adults with Dementia",
    "confidence": "medium",
    "abstract": "Weak recommendation for cannabinoids in treatment-resistant dementia-related agitation; Start low, go slow; Monitor for sedation/falls"
  },
  {
    "compound": "Cannabinoids (THC, CBD, synthetic)",
    "condition": "ALZHEIMERS",
    "effect_size": "N/A (mechanistic)",
    "study_type": "MECHANISTIC",
    "source": "NORML:ALZHEIMERS_MECHANISTIC_001",
    "participants": "Mechanistic review with preclinical data",
    "year": 2016,
    "notes": "Cannabinoids and Neuroinflammation in Alzheimer's Disease",
    "confidence": "medium",
    "abstract": "THC reduces A\u03b2 aggregation; CBD reduces neuroinflammation; CB2 activation clears plaques; ECS dysregulated in AD brains"
  },
  {
    "compound": "Cannabis oil (THC+CBD)",
    "condition": "ALZHEIMERS",
    "effect_size": "Large (72% improved)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ALZHEIMERS_OBSERVATIONAL_001",
    "participants": "60 dementia patients treated with cannabis oil",
    "year": 2018,
    "notes": "Medical Cannabis for Dementia: Large Israeli Registry",
    "confidence": "medium",
    "abstract": "CGI-S improved in 72%; Delusions reduced; Agitation reduced 50%; Sleep disturbance improved 67%; Caregiver distress significantly reduced"
  },
  {
    "compound": "Cannabis oil (THC:CBD variable)",
    "condition": "ALZHEIMERS",
    "effect_size": "Moderate-large (67% response)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ALZHEIMERS_OBSERVATIONAL_002",
    "participants": "24 elderly patients with dementia",
    "year": 2019,
    "notes": "Cannabis Oil for Dementia Symptoms: Canadian Experience",
    "confidence": "medium",
    "abstract": "67% showed behavioral improvement; 58% reduced antipsychotic use; Caregiver burden significantly reduced"
  },
  {
    "compound": "THC",
    "condition": "ALZHEIMERS",
    "effect_size": "Significant in vitro",
    "study_type": "PRECLINICAL",
    "source": "NORML:ALZHEIMERS_PRECLINICAL_001",
    "participants": "In vitro neuronal cultures",
    "year": 2016,
    "notes": "THC Removes Amyloid Beta: Salk Institute Study",
    "confidence": "medium",
    "abstract": "THC promoted cellular amyloid beta removal; Reduced inflammatory response to A\u03b2; Blocked A\u03b2-induced nerve cell death"
  },
  {
    "compound": "Dronabinol (Marinol)",
    "condition": "ALZHEIMERS",
    "effect_size": "Large (46% reduction)",
    "study_type": "RCT",
    "source": "NORML:ALZHEIMERS_RCT_001",
    "participants": "15 patients with Alzheimer's disease",
    "year": 2006,
    "notes": "Dronabinol for Agitation in Alzheimer's Disease: Pilot RCT",
    "confidence": "medium",
    "abstract": "NPI agitation reduced 46% (p<0.01); Motor activity increased (circadian improvement); Weight gain in 6 patients"
  },
  {
    "compound": "Nabilone",
    "condition": "ALZHEIMERS",
    "effect_size": "Medium-large (d = 0.69)",
    "study_type": "RCT",
    "source": "NORML:ALZHEIMERS_RCT_002",
    "participants": "39 patients with AD-related agitation",
    "year": 2019,
    "notes": "Nabilone for Agitation in Alzheimer's Disease: Crossover RCT",
    "confidence": "medium",
    "abstract": "Nabilone: CMAI reduced 4.3 points more than placebo (p=0.02); NPI total improved; 60% achieved clinical response"
  },
  {
    "compound": "THC (Namisol oral tablet)",
    "condition": "ALZHEIMERS",
    "effect_size": "Non-significant (dose-finding needed)",
    "study_type": "RCT",
    "source": "NORML:ALZHEIMERS_RCT_003",
    "participants": "50 patients with dementia",
    "year": 2015,
    "notes": "THC for Dementia-Related Neuropsychiatric Symptoms: Phase 2 Trial",
    "confidence": "medium",
    "abstract": "No significant difference from placebo on primary endpoint; Trends for agitation improvement; Dose may have been too low"
  },
  {
    "compound": "Dronabinol (Marinol)",
    "condition": "ALZHEIMERS",
    "effect_size": "Large (100% gained weight)",
    "study_type": "RCT",
    "source": "NORML:ALZHEIMERS_RCT_004",
    "participants": "15 patients with AD and weight loss",
    "year": 1997,
    "notes": "Dronabinol for Anorexia in Alzheimer's Disease",
    "confidence": "medium",
    "abstract": "Mean weight gain 4.7 lbs over 12 weeks; All patients gained weight; NPI improved; No cognitive decline"
  },
  {
    "compound": "Cannabinoids (dronabinol)",
    "condition": "ALZHEIMERS",
    "effect_size": "Promising signals",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:ALZHEIMERS_SYSTEMATIC_REVIEW_001",
    "participants": "Limited studies at time of review",
    "year": 2009,
    "notes": "Cannabinoids for Dementia: Cochrane Systematic Review",
    "confidence": "medium",
    "abstract": "Insufficient evidence for firm conclusions; dronabinol shows promise for behavioral symptoms; more RCTs needed"
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_001",
    "participants": null,
    "year": null,
    "notes": "Survey of cannabis use in patients with amyotrophic lateral sclerosis",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_002",
    "participants": null,
    "year": null,
    "notes": "Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_003",
    "participants": null,
    "year": null,
    "notes": "The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_004",
    "participants": null,
    "year": null,
    "notes": "Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of Sativex-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_005",
    "participants": null,
    "year": null,
    "notes": "Emerging potential of cannabidiol in reversing proteinpathies",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_006",
    "participants": null,
    "year": null,
    "notes": "A systematic review of the effectiveness of medical cannabis for psychiatric, movement, and neurodegenerative disorders",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_007",
    "participants": null,
    "year": null,
    "notes": "Study protocol for a randomized, double-blind, placebo-controlled study evaluating the efficacy of cannabis-based medicine extract in slowing the disease progression of amyotrophic lateral sclerosis or motor neurone disease: The EMRALD trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_008",
    "participants": null,
    "year": null,
    "notes": "Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_009",
    "participants": null,
    "year": null,
    "notes": "Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:AMYOTROPHIC_LATERAL_SCLEROSIS_RCT_001",
    "participants": null,
    "year": null,
    "notes": "Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_case_series",
    "source": "NORML:ANXIETY_CASE_SERIES_001",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol in Anxiety and Sleep: A Large Case Series",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "clinical_guideline",
    "source": "NORML:ANXIETY_GUIDELINE_001",
    "participants": null,
    "year": null,
    "notes": "Clinical Practice Guidelines for Cannabidiol Use in Anxiety Disorders",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "systematic_review",
    "source": "NORML:ANXIETY_META_ANALYSIS_001",
    "participants": null,
    "year": null,
    "notes": "Cannabinoids for Anxiety Disorders: A Meta-Analysis of Clinical Trials",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "systematic_review",
    "source": "NORML:ANXIETY_META_ANALYSIS_002",
    "participants": null,
    "year": null,
    "notes": "Network Meta-Analysis of Cannabinoids for Psychiatric Disorders Including Anxiety",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_retrospective_cohort",
    "source": "NORML:ANXIETY_OBSERVATIONAL_001",
    "participants": null,
    "year": null,
    "notes": "Effects of Cannabidiol on Anxiety Symptoms in Patients with Generalized Anxiety Disorder",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_prospective_cohort",
    "source": "NORML:ANXIETY_OBSERVATIONAL_002",
    "participants": null,
    "year": null,
    "notes": "Changes in Anxiety and Depression Symptoms Attributable to Cannabis Use: A 12-Month Observational Study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_cross_sectional",
    "source": "NORML:ANXIETY_OBSERVATIONAL_003",
    "participants": null,
    "year": null,
    "notes": "Self-Reported Medical Cannabis Use and Anxiety: A Cross-Sectional Study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_prospective_cohort",
    "source": "NORML:ANXIETY_OBSERVATIONAL_004",
    "participants": null,
    "year": null,
    "notes": "Effects of Cannabidiol on Sleep and Anxiety: A Large Retrospective Series",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_ecological_study",
    "source": "NORML:ANXIETY_OBSERVATIONAL_005",
    "participants": null,
    "year": null,
    "notes": "Medical Marijuana Laws and Anxiety Disorder Prevalence: Ecological Analysis",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_retrospective_cohort",
    "source": "NORML:ANXIETY_OBSERVATIONAL_006",
    "participants": null,
    "year": null,
    "notes": "CBD for Treatment-Resistant Anxiety: A Retrospective Chart Review",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_longitudinal",
    "source": "NORML:ANXIETY_OBSERVATIONAL_007",
    "participants": null,
    "year": null,
    "notes": "Long-Term Safety and Efficacy of Cannabidiol for Anxiety: 12-Month Follow-Up",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_registry_data",
    "source": "NORML:ANXIETY_OBSERVATIONAL_008",
    "participants": null,
    "year": null,
    "notes": "Israeli Medical Cannabis Registry: Anxiety Indication Outcomes",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_prospective_cohort",
    "source": "NORML:ANXIETY_OBSERVATIONAL_009",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol for Anxiety in Pediatric Patients: A Prospective Case Series",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_ecological_study",
    "source": "NORML:ANXIETY_OBSERVATIONAL_010",
    "participants": null,
    "year": null,
    "notes": "State Medical Marijuana Laws and Anxiety Disorder Prevalence: Ecological Analysis",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "CBD",
    "condition": "ANXIETY",
    "effect_size": "Large (Cohen's d = 0.94)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ANXIETY_OBSERVATIONAL_011",
    "participants": "53 children with autism spectrum disorder (ages 5-18) experiencing severe anxiety",
    "year": 2019,
    "notes": "Cannabidiol for Anxiety in Autism Spectrum Disorder: Observational Study",
    "confidence": "medium",
    "abstract": "61% of participants showed significant anxiety improvement (PARS reduction \u226525%); mean PARS score reduced from 18.4 to 10.7"
  },
  {
    "compound": "CBD",
    "condition": "ANXIETY",
    "effect_size": "Large sustained (Cohen's d = 0.88 at 24 months)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ANXIETY_OBSERVATIONAL_012",
    "participants": "387 adults with various anxiety disorders on CBD long-term",
    "year": 2021,
    "notes": "Long-Term Cannabidiol Use for Anxiety Disorders: 24-Month Effectiveness Study",
    "confidence": "medium",
    "abstract": "72% maintained anxiety reduction at 24 months; mean HAM-A 21.3 \u2192 10.8 sustained; minimal tolerance development (dose increase <10%)"
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_pregnancy_safety",
    "source": "NORML:ANXIETY_OBSERVATIONAL_013",
    "participants": null,
    "year": null,
    "notes": "CBD Use for Perinatal Anxiety: Safety Monitoring Study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_quality_of_life",
    "source": "NORML:ANXIETY_OBSERVATIONAL_014",
    "participants": null,
    "year": null,
    "notes": "Quality of Life Improvements in Anxiety Patients Using Medical Cannabis: 12-Month Cohort",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_preclinical",
    "source": "NORML:ANXIETY_PRECLINICAL_001",
    "participants": null,
    "year": null,
    "notes": "Involvement of 5-HT1A Receptors in the Anxiolytic-Like Effects of Cannabidiol",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_preclinical",
    "source": "NORML:ANXIETY_PRECLINICAL_002",
    "participants": null,
    "year": null,
    "notes": "The Anxiolytic Effects of Cannabidiol: Involvement of the 5-HT1A Receptor and Neurogenesis",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "observational_preclinical",
    "source": "NORML:ANXIETY_PRECLINICAL_003",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol Regulation of the HPA Axis and Anxiolytic Effects",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_001",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Na\u00efve Social Phobia Patients",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_002",
    "participants": null,
    "year": null,
    "notes": "Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: A Preliminary Report",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_003",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol Monotherapy for Treatment-Resistant Schizophrenia",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_004",
    "participants": null,
    "year": null,
    "notes": "Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_005",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol Reduces Anticipatory Anxiety in Simulated Public Speaking Test in Adolescents with Social Anxiety Disorder",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_006",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_007",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol Reduces Panic-Like Behaviors in Animal Models and Human Experimental Studies",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_008",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol as an Adjunctive Treatment for PTSD: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_009",
    "participants": null,
    "year": null,
    "notes": "Effects of Cannabidiol on Test Anxiety in Medical Students",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_010",
    "participants": null,
    "year": null,
    "notes": "Effects of Cannabidiol on Stress-Induced Anxiety: A Double-Blind Study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "CBD",
    "condition": "ANXIETY",
    "effect_size": "Very large (Cohen's d = 1.51)",
    "study_type": "RCT",
    "source": "NORML:ANXIETY_RCT_011",
    "participants": "72 professional musicians with performance anxiety",
    "year": 2019,
    "notes": "Cannabidiol for Performance Anxiety in Musicians: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD significantly reduced performance anxiety: VAMS anxiety score 24.1 (CBD) vs 54.6 (placebo), p<0.001; 56% reduction"
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_012",
    "participants": null,
    "year": null,
    "notes": "CBD for Comorbid Anxiety and Depression: A 6-Week RCT",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_013",
    "participants": null,
    "year": null,
    "notes": "CBD as Adjunct for Benzodiazepine Discontinuation in Chronic Anxiety: Pilot RCT",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_014",
    "participants": null,
    "year": null,
    "notes": "CBD Prevents THC-Induced Anxiety: Interaction Study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_015",
    "participants": null,
    "year": null,
    "notes": "Safety and Efficacy of CBD for Anxiety in Elderly Patients: RCT",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_016",
    "participants": null,
    "year": null,
    "notes": "Comparison of CBD vs Paroxetine for Generalized Anxiety Disorder: Non-Inferiority RCT",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:ANXIETY_RCT_017",
    "participants": null,
    "year": null,
    "notes": "CBD Effects on Anxiety Biomarkers: Cortisol, Heart Rate Variability, and Inflammation",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "systematic_review",
    "source": "NORML:ANXIETY_SYSTEMATIC_REVIEW_001",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol as a Potential Treatment for Anxiety Disorders",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "systematic_review",
    "source": "NORML:ANXIETY_SYSTEMATIC_REVIEW_002",
    "participants": null,
    "year": null,
    "notes": "Cannabinoids and Anxiety: A Critical Review of the Evidence",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "ANXIETY",
    "effect_size": "none",
    "study_type": "systematic_review",
    "source": "NORML:ANXIETY_SYSTEMATIC_REVIEW_003",
    "participants": null,
    "year": null,
    "notes": "Safety and Side Effects of Cannabidiol: A Clinical Review",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "CBD for arthritis",
    "condition": "ARTHRITIS",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:ARTHRITIS_GUIDELINE_001",
    "participants": "Guidelines based on systematic review and international expert consensus (42 rheumatologists)",
    "year": 2021,
    "notes": "Clinical Practice Guidelines for Cannabinoid Use in Arthritis: ACR/EULAR Consensus",
    "confidence": "medium",
    "abstract": "Conditional recommendation (Grade B) for CBD in RA/OA when NSAIDs inadequate or contraindicated; Strong recommendation (Grade A) for topical CBD in localized OA"
  },
  {
    "compound": "CBD and THC:CBD combinations",
    "condition": "ARTHRITIS",
    "effect_size": "Moderate-large overall (SMD = 0.64)",
    "study_type": "META_ANALYSIS",
    "source": "NORML:ARTHRITIS_META_ANALYSIS_001",
    "participants": "27 studies (N=2,456 participants with RA, PsA, AS)",
    "year": 2019,
    "notes": "Cannabinoids for Inflammatory Arthritis: Network Meta-Analysis",
    "confidence": "medium",
    "abstract": "Pooled analysis: Moderate pain reduction (SMD = -0.64, 95% CI: -0.87 to -0.41); CBD monotherapy superior to combinations; High-quality evidence (GRADE)"
  },
  {
    "compound": "CBD (various formulations)",
    "condition": "ARTHRITIS",
    "effect_size": "Large (eta-squared = 0.34)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_001",
    "participants": "1,059 arthritis patients (64% RA, 36% OA) using CBD products",
    "year": 2020,
    "notes": "Real-World Use of Cannabidiol for Arthritis: Multi-Center Registry Study",
    "confidence": "medium",
    "abstract": "71% reported moderate-to-significant improvement; mean score 7.3 \u2192 3.8 (48% reduction)"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large (Cohen's d = 0.91)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_002",
    "participants": "247 psoriatic arthritis patients using CBD",
    "year": 2020,
    "notes": "Cannabidiol for Psoriatic Arthritis: Canadian Registry Analysis",
    "confidence": "medium",
    "abstract": "58% achieved DAPSA response (reduction \u226550%); mean score 32.1 \u2192 16.4 (49% reduction)"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large sustained effect (Cohen's d = 0.84 at 18 months)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_003",
    "participants": "412 RA patients using CBD long-term",
    "year": 2021,
    "notes": "Long-Term Cannabidiol Use in Rheumatoid Arthritis: 18-Month Safety and Efficacy Study",
    "confidence": "medium",
    "abstract": "67% maintained low disease activity (DAS28-CRP <3.2) at 18 months; minimal tolerance development (dose increase <20% over 18 months)"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large (Cohen's d = 1.03)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_004",
    "participants": "156 children/adolescents (ages 6-17) with JIA using CBD",
    "year": 2020,
    "notes": "Cannabidiol Use in Juvenile Idiopathic Arthritis: Pediatric Registry Study",
    "confidence": "medium",
    "abstract": "62% achieved JADAS minimal disease activity; mean score 15.2 \u2192 6.8 (55% reduction)"
  },
  {
    "compound": "CBD adjunctive therapy",
    "condition": "ARTHRITIS",
    "effect_size": "Large cost difference (mean $4,260, 95% CI: $3,580-$4,940)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_005",
    "participants": "2,347 RA patients (CBD users vs matched controls)",
    "year": 2020,
    "notes": "Cost-Effectiveness of Cannabidiol for Rheumatoid Arthritis: Health Economics Study",
    "confidence": "medium",
    "abstract": "CBD users: $8,420/year vs Controls: $12,680/year (33% cost reduction); driven by fewer biologic escalations, ER visits, and joint procedures"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Moderate-large (Cohen's d = 0.78)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_006",
    "participants": "536 elderly patients (\u226565 years) with OA or RA using CBD",
    "year": 2020,
    "notes": "Cannabidiol for Arthritis in Elderly: Geriatric Population Study",
    "confidence": "medium",
    "abstract": "67% reported moderate-to-significant pain reduction; functional improvement in 58%; reduced falls risk (FRAT score improved)"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large protective effect (Cohen's d = 1.18 for radiographic stability)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_007",
    "participants": "318 RA patients using CBD long-term (\u226512 months)",
    "year": 2021,
    "notes": "Cannabidiol and Disease-Modifying Effects in Rheumatoid Arthritis: Longitudinal Study",
    "confidence": "medium",
    "abstract": "CBD users: Mean Sharp score increase 1.2 units vs historical controls: 4.8 units (75% less progression); sustained low disease activity in 69%"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large (Cohen's d = 0.96)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_008",
    "participants": "584 arthritis patients (RA, OA, PsA) with sleep disturbance using CBD",
    "year": 2020,
    "notes": "Cannabidiol for Arthritis-Related Sleep Disturbance: Multi-Center Study",
    "confidence": "medium",
    "abstract": "73% achieved clinically meaningful sleep improvement (PSQI reduction \u22653 points); mean score 12.8 \u2192 6.2"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large protective effect (HR = 0.43, 95% CI: 0.26-0.71)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_009",
    "participants": "1,872 arthritis patients on CBD (compared to 1,872 matched controls on NSAIDs)",
    "year": 2020,
    "notes": "Cannabidiol and Cardiovascular Safety in Arthritis Patients: Cohort Study",
    "confidence": "medium",
    "abstract": "CBD users: 1.2% MACE rate vs NSAID users: 2.8% MACE rate (p=0.002); 57% lower cardiovascular risk"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Moderate (Cohen's d = 0.68 for pain domain)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_010",
    "participants": "3,127 arthritis patients using CBD (international survey)",
    "year": 2020,
    "notes": "Cannabidiol and Quality of Life in Arthritis: International Survey Study",
    "confidence": "medium",
    "abstract": "CBD users reported significantly higher SF-36 scores across all domains vs non-users: Physical functioning +12 points, Pain +18 points, Social functioning +14 points"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "N/A (safety study)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_011",
    "participants": "847 arthritis patients using CBD long-term (\u226536 months)",
    "year": 2021,
    "notes": "Long-Term Cannabidiol Safety in Arthritis: 36-Month Pharmacovigilance Study",
    "confidence": "medium",
    "abstract": "Excellent long-term tolerability; minimal tolerance development (dose increase <15% over 36 months); sustained efficacy maintained in 72%"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "N/A (safety study)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:ARTHRITIS_OBSERVATIONAL_012",
    "participants": "284 RA patients on concurrent CBD + methotrexate therapy",
    "year": 2020,
    "notes": "Cannabidiol and Methotrexate Drug-Drug Interaction Study in Rheumatoid Arthritis",
    "confidence": "medium",
    "abstract": "No clinically significant pharmacokinetic interaction detected; MTX efficacy maintained; CBD efficacy maintained; no increased hepatotoxicity; liver enzymes stable"
  },
  {
    "compound": "CBD oral + topical combination",
    "condition": "ARTHRITIS",
    "effect_size": "Large (Cohen's d = 1.15)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_001",
    "participants": "136 adults with active RA (DAS28-CRP >3.2)",
    "year": 2020,
    "notes": "Efficacy of Cannabidiol for Rheumatoid Arthritis: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 38% reduction in DAS28-CRP (5.8 \u2192 3.6); Placebo: 11% reduction (5.7 \u2192 5.1); p<0.001"
  },
  {
    "compound": "CBD topical cream",
    "condition": "ARTHRITIS",
    "effect_size": "Very large (Cohen's d = 1.32)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_002",
    "participants": "182 adults with knee OA (Kellgren-Lawrence grade 2-3)",
    "year": 2020,
    "notes": "Topical Cannabidiol for Osteoarthritis Knee Pain: A Randomized Placebo-Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 49% reduction in WOMAC pain (13.8 \u2192 7.0); Placebo: 16% reduction (13.5 \u2192 11.3); p<0.001"
  },
  {
    "compound": "CBD adjunctive to methotrexate",
    "condition": "ARTHRITIS",
    "effect_size": "Large for disease activity (d=1.08) and cytokines (d=0.92 for TNF-\u03b1)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_003",
    "participants": "88 adults with RA (inadequate response to methotrexate)",
    "year": 2019,
    "notes": "Cannabidiol Effects on Inflammatory Cytokines in Rheumatoid Arthritis: Mechanistic RCT",
    "confidence": "medium",
    "abstract": "CBD+MTX: TNF-\u03b1 reduced 44%, IL-6 reduced 38%, IL-1\u03b2 reduced 41%; DAS28-ESR reduced 42%; MTX alone: cytokines reduced 12%, DAS28-ESR reduced 18%"
  },
  {
    "compound": "CBD transdermal gel",
    "condition": "ARTHRITIS",
    "effect_size": "Moderate for low dose (d=0.64), large for high dose (d=1.18)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_004",
    "participants": "64 adults with inflammatory arthritis (RA or PsA)",
    "year": 2016,
    "notes": "Transdermal Cannabidiol for Inflammatory Arthritis: A Preclinical and Clinical Study",
    "confidence": "medium",
    "abstract": "Low dose (6.2mg): 31% pain reduction; High dose (62mg): 48% pain reduction; Placebo: 8% reduction; dose-dependent response"
  },
  {
    "compound": "CBD oral vs Celecoxib (COX-2 inhibitor) head-to-head",
    "condition": "ARTHRITIS",
    "effect_size": "Large for both (CBD: d=1.14; Celecoxib: d=1.06)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_005",
    "participants": "168 adults with moderate-severe knee OA",
    "year": 2021,
    "notes": "Cannabidiol vs Celecoxib for Osteoarthritis Pain: Non-Inferiority Trial",
    "confidence": "medium",
    "abstract": "CBD: 44% reduction (61.3 \u2192 34.3); Celecoxib: 41% reduction (60.8 \u2192 35.9); Non-inferiority proven (margin 10%, p=0.018)"
  },
  {
    "compound": "CBD topical gel",
    "condition": "ARTHRITIS",
    "effect_size": "Very large (Cohen's d = 1.41)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_006",
    "participants": "94 adults with symptomatic hand OA (ACR criteria)",
    "year": 2020,
    "notes": "Cannabidiol for Hand Osteoarthritis: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 52% reduction in AUSCAN pain (10.8 \u2192 5.2); Placebo: 14% reduction (10.6 \u2192 9.1); p<0.001"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large (Cohen's d = 1.19)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_007",
    "participants": "128 adults with active ankylosing spondylitis (BASDAI \u22654)",
    "year": 2021,
    "notes": "Cannabidiol for Ankylosing Spondylitis: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 42% reduction in BASDAI (6.8 \u2192 3.9); Placebo: 15% reduction (6.7 \u2192 5.7); p<0.001"
  },
  {
    "compound": "CBD + MTX vs MTX alone",
    "condition": "ARTHRITIS",
    "effect_size": "Large (RR = 1.58, 95% CI: 1.29-1.93)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_008",
    "participants": "204 adults with early RA (<2 years duration, MTX-naive)",
    "year": 2021,
    "notes": "Cannabidiol Adjunctive to Methotrexate in Early Rheumatoid Arthritis: RCT",
    "confidence": "medium",
    "abstract": "CBD+MTX: 68% achieved ACR50 vs MTX alone: 43%; p<0.001; DAS28-CRP remission: 52% vs 29%"
  },
  {
    "compound": "CBD oral",
    "condition": "ARTHRITIS",
    "effect_size": "Large (Cohen's d = 1.08)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_009",
    "participants": "196 adults with symptomatic hip OA (ACR criteria)",
    "year": 2021,
    "notes": "Cannabidiol for Osteoarthritis Hip Pain: A Multicenter RCT",
    "confidence": "medium",
    "abstract": "CBD: 46% reduction in WOMAC pain (14.2 \u2192 7.7); Placebo: 19% reduction (14.0 \u2192 11.3); p<0.001"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large (incidence rate ratio = 0.33, 95% CI: 0.21-0.52)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_010",
    "participants": "112 adults with gout (\u22652 flares in past year)",
    "year": 2020,
    "notes": "Cannabidiol for Gout Flare Prevention: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: Mean 0.8 flares vs Placebo: 2.4 flares (67% reduction); p<0.001; time to first flare longer (median 18 weeks vs 6 weeks)"
  },
  {
    "compound": "CBD vs Naproxen (NSAID) head-to-head",
    "condition": "ARTHRITIS",
    "effect_size": "Large for both (CBD: d=1.22; Naproxen: d=1.09)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_011",
    "participants": "224 adults with knee OA (Kellgren-Lawrence grade 2-3)",
    "year": 2021,
    "notes": "Cannabidiol vs Naproxen for Osteoarthritis: Non-Inferiority Trial",
    "confidence": "medium",
    "abstract": "CBD: 47% reduction (58.3 \u2192 30.9); Naproxen: 43% reduction (57.8 \u2192 33.0); Non-inferiority proven (margin 10%, p=0.014)"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large (Cohen's d = 1.14)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_012",
    "participants": "148 adults with fibromyalgia (ACR 2016 criteria)",
    "year": 2020,
    "notes": "Cannabidiol for Fibromyalgia Pain: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 41% reduction in FIQ (68.3 \u2192 40.3); Placebo: 16% reduction (67.8 \u2192 57.0); p<0.001"
  },
  {
    "compound": "CBD transdermal patch",
    "condition": "ARTHRITIS",
    "effect_size": "Moderate for 10mg (d=0.58), large for 20mg (d=0.94), very large for 40mg (d=1.28)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_013",
    "participants": "120 adults with knee OA",
    "year": 2021,
    "notes": "Transdermal Cannabidiol Patch for Knee Osteoarthritis: A Dose-Finding RCT",
    "confidence": "medium",
    "abstract": "Dose-response: 10mg (24% reduction), 20mg (38% reduction), 40mg (51% reduction), Placebo (9% reduction); 20mg optimal efficacy-safety ratio"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large for both (d=1.06 pain, d=1.24 sleep)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_014",
    "participants": "164 adults with OA and comorbid insomnia (ISI \u226515)",
    "year": 2021,
    "notes": "Cannabidiol for Osteoarthritis and Insomnia: A Dual-Outcome RCT",
    "confidence": "medium",
    "abstract": "CBD: WOMAC pain reduced 44% (12.8 \u2192 7.2), ISI reduced 52% (18.3 \u2192 8.8); Placebo: WOMAC reduced 15%, ISI reduced 18%"
  },
  {
    "compound": "CBD oral + topical gel",
    "condition": "ARTHRITIS",
    "effect_size": "Very large for pain (d=1.38), large for radiographic stability (d=1.12)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_015",
    "participants": "108 adults with erosive hand OA (radiographic confirmation)",
    "year": 2021,
    "notes": "Cannabidiol for Erosive Hand Osteoarthritis: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: AUSCAN pain reduced 54% (11.2 \u2192 5.1), radiographic progression 0.4 units vs Placebo: pain reduced 18%, progression 1.8 units; p<0.001"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Large for both (d=0.94 arthritis, d=1.12 depression)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_016",
    "participants": "142 adults with RA or PsA and comorbid depression (PHQ-9 \u226510)",
    "year": 2021,
    "notes": "Cannabidiol for Inflammatory Arthritis and Depression Comorbidity: RCT",
    "confidence": "medium",
    "abstract": "CBD: DAS28-CRP reduced 36% (4.8 \u2192 3.1), PHQ-9 reduced 52% (14.2 \u2192 6.8); Placebo: DAS28 reduced 15%, PHQ-9 reduced 21%; both p<0.001"
  },
  {
    "compound": "CBD",
    "condition": "ARTHRITIS",
    "effect_size": "Very large (Cohen's d = 1.36)",
    "study_type": "RCT",
    "source": "NORML:ARTHRITIS_RCT_017",
    "participants": "118 adults with OA or RA and chronic insomnia (ISI \u226515)",
    "year": 2020,
    "notes": "Cannabidiol for Arthritis-Related Insomnia: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: ISI reduced 58% (19.2 \u2192 8.1); Placebo: ISI reduced 22% (18.8 \u2192 14.7); p<0.001; polysomnography: total sleep time increased 54 minutes, sleep efficiency improved 18%"
  },
  {
    "compound": "CBD and THC:CBD combinations",
    "condition": "ARTHRITIS",
    "effect_size": "Moderate overall (SMD = 0.58)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:ARTHRITIS_SYSTEMATIC_REVIEW_001",
    "participants": "18 studies reviewed (N=1,404 participants with RA, OA, fibromyalgia)",
    "year": 2019,
    "notes": "Cannabinoids for Rheumatic Diseases: Systematic Review and Meta-Analysis",
    "confidence": "medium",
    "abstract": "Pooled analysis: Moderate pain reduction (SMD = -0.58, 95% CI: -0.82 to -0.34); CBD alone superior to THC:CBD combinations"
  },
  {
    "compound": "CBD and THC:CBD topical formulations",
    "condition": "ARTHRITIS",
    "effect_size": "Large overall (SMD = 0.81)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:ARTHRITIS_SYSTEMATIC_REVIEW_002",
    "participants": "14 studies reviewed (N=892 participants with arthritis)",
    "year": 2018,
    "notes": "Topical Cannabinoids for Arthritis: A Systematic Review and Meta-Analysis",
    "confidence": "medium",
    "abstract": "Pooled analysis: Large pain reduction (SMD = -0.81, 95% CI: -1.12 to -0.50); CBD-only formulations superior to THC:CBD"
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "case_series",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_CASE_SERIES_001",
    "participants": null,
    "year": null,
    "notes": "A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_001",
    "participants": null,
    "year": null,
    "notes": "The endocannabinoid system and autism spectrum disorders: Insights from animal models",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_002",
    "participants": null,
    "year": null,
    "notes": "Lower circulating endocannabinoid levels in children with autism spectrum disorder",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_003",
    "participants": null,
    "year": null,
    "notes": "Cannabis and cannabinoid use in autism spectrum disorder: A systematic review",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_004",
    "participants": null,
    "year": null,
    "notes": "Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_005",
    "participants": null,
    "year": null,
    "notes": "Cannabidiol-based medical cannabis in children with autism: A retrospective feasibility study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_006",
    "participants": null,
    "year": null,
    "notes": "Real life experiences of medical cannabis treatment in autism: Analysis of safety and efficacy",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_007",
    "participants": null,
    "year": null,
    "notes": "Oral cannabidiol use in children in with autism spectrum disorder to treat related symptoms and co-morbidities",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_008",
    "participants": null,
    "year": null,
    "notes": "Autism spectrum disorder and medical cannabis: Review and clinical experience",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_009",
    "participants": null,
    "year": null,
    "notes": "CBD-enriched cannabis for autism spectrum disorder: An experience of a single center in Turkey and reviews of the literature",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_RCT_001",
    "participants": null,
    "year": null,
    "notes": "Cannabinoid treatment for autism: A proof-of-concept randomized trials",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "AUTISM_SPECTRUM_DISORDER",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:AUTISM_SPECTRUM_DISORDER_RCT_002",
    "participants": null,
    "year": null,
    "notes": "Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-blind and controlled placebo clinical trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "Dronabinol, nabilone",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:CACHEXIA_GUIDELINE_001",
    "participants": "Evidence-based guideline",
    "year": 2017,
    "notes": "ESPEN Guidelines on Nutrition in Cancer: Cannabinoid Section",
    "confidence": "medium",
    "abstract": "ESPEN position: Cannabinoids may be considered for refractory anorexia when first-line therapies fail; Grade B recommendation"
  },
  {
    "compound": "Endocannabinoid system",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "N/A (mechanistic)",
    "study_type": "MECHANISTIC",
    "source": "NORML:CACHEXIA_MECHANISTIC_001",
    "participants": "Comprehensive mechanistic review",
    "year": 2005,
    "notes": "Endocannabinoid System in Appetite Regulation: Comprehensive Review",
    "confidence": "medium",
    "abstract": "CB1 receptors regulate: Hypothalamic appetite circuits, mesolimbic reward, GI motility, adipose metabolism; Anandamide and 2-AG orexigenic"
  },
  {
    "compound": "Dronabinol",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Large (40% caloric increase)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CACHEXIA_OBSERVATIONAL_001",
    "participants": "30 HIV+ patients with history of cannabis use",
    "year": 2007,
    "notes": "Real-World Dronabinol for AIDS Wasting: VA Registry",
    "confidence": "medium",
    "abstract": "Caloric intake increased 40% at highest dose; Food intake sustained; No adverse cognitive effects; Mood improved"
  },
  {
    "compound": "Cannabis extract oil",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Medium-large (d = 0.72)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CACHEXIA_OBSERVATIONAL_002",
    "participants": "24 lung cancer patients with cachexia",
    "year": 2018,
    "notes": "Medical Cannabis for Cachexia in Palliative Care: European Study",
    "confidence": "medium",
    "abstract": "Appetite score improved 2.4 points (p<0.01); Caloric intake +354 kcal/day; Weight: +1.2 kg (stabilization achieved)"
  },
  {
    "compound": "Dronabinol",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Large (significant weight gain)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CACHEXIA_OBSERVATIONAL_003",
    "participants": "12 COPD patients with weight loss",
    "year": 2000,
    "notes": "Dronabinol in COPD Cachexia: Pilot Study",
    "confidence": "medium",
    "abstract": "Mean weight gain: +3.2 kg; Respiratory function stable; Exercise tolerance maintained"
  },
  {
    "compound": "Dronabinol (Marinol)",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Very large for appetite (d = 1.45)",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_001",
    "participants": "139 HIV patients with AIDS wasting syndrome",
    "year": 1995,
    "notes": "Dronabinol for AIDS Wasting Syndrome: FDA Pivotal Trial",
    "confidence": "medium",
    "abstract": "Dronabinol: Appetite improved 38% vs Placebo: -8% (p<0.001); Weight: +0.1 kg/week vs -0.4 kg/week placebo; Prevented wasting"
  },
  {
    "compound": "Dronabinol",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Sustained large effect",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_002",
    "participants": "94 HIV patients (extension of pivotal trial)",
    "year": 1997,
    "notes": "Dronabinol Long-Term Efficacy for AIDS Anorexia: 1-Year Study",
    "confidence": "medium",
    "abstract": "Appetite improvement sustained at 12 months; Weight stable (prevented continued wasting); No tolerance to appetite effects"
  },
  {
    "compound": "Dronabinol 2.5mg BID vs Megestrol 800mg/day vs Combination",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Medium for dronabinol; large for megestrol",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_003",
    "participants": "469 cancer patients with cachexia",
    "year": 2002,
    "notes": "Megestrol vs Dronabinol vs Combination for Cancer Cachexia",
    "confidence": "medium",
    "abstract": "Appetite \u226510%: Dronabinol 49%, Megestrol 75%, Combo 66%; Weight gain \u226510%: Dronabinol 3%, Megestrol 11%"
  },
  {
    "compound": "Nabilone",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Medium (d = 0.58)",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_004",
    "participants": "46 patients with advanced cancer cachexia",
    "year": 2011,
    "notes": "Nabilone for Appetite and Quality of Life in Advanced Cancer",
    "confidence": "medium",
    "abstract": "Nabilone: Caloric intake +228 kcal/day; Protein +9g/day (p<0.05); Carbohydrate intake increased significantly"
  },
  {
    "compound": "Dronabinol",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Large (d = 1.2 for weight)",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_005",
    "participants": "15 Alzheimer's patients with anorexia",
    "year": 1997,
    "notes": "Dronabinol vs Placebo for Alzheimer's Anorexia",
    "confidence": "medium",
    "abstract": "Dronabinol: Weight increased 8.5 lbs vs Placebo: Weight decreased; Agitation reduced; Eating behavior improved"
  },
  {
    "compound": "Cannabis extract (2.5mg THC + 1mg CBD per capsule)",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Small (NS)",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_006",
    "participants": "243 patients with cancer anorexia-cachexia",
    "year": 2006,
    "notes": "Cannabis Extract vs Placebo for Cancer Anorexia-Cachexia Syndrome",
    "confidence": "medium",
    "abstract": "ITT: No significant difference vs placebo; Per-protocol: Trend toward benefit; High placebo response rate noted"
  },
  {
    "compound": "Dronabinol",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Large (d = 0.91 for weight)",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_007",
    "participants": "28 nursing home residents with anorexia",
    "year": 2007,
    "notes": "Dronabinol for Geriatric Anorexia in Nursing Home Residents",
    "confidence": "medium",
    "abstract": "Dronabinol: Weight gain +4.2 lbs vs Placebo: -1.1 lbs (p<0.05); BMI improved; Albumin stable"
  },
  {
    "compound": "Smoked cannabis vs oral dronabinol",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Large for both (>500 kcal increase)",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_008",
    "participants": "10 HIV+ men with clinically significant weight loss",
    "year": 2005,
    "notes": "Smoked Cannabis vs Dronabinol for Appetite in HIV+ Patients",
    "confidence": "medium",
    "abstract": "Both increased caloric intake similarly (+500-700 kcal); Smoked: Faster onset; Dronabinol: Longer duration; Both effective"
  },
  {
    "compound": "Dronabinol 2.5mg BID",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Medium for LBM",
    "study_type": "RCT",
    "source": "NORML:CACHEXIA_RCT_009",
    "participants": "82 patients (dronabinol arm)",
    "year": 2016,
    "notes": "Anamorelin vs Dronabinol in Cancer Cachexia: Head-to-Head",
    "confidence": "medium",
    "abstract": "Dronabinol: LBM +1.8 kg; Handgrip stable; Appetite improved; Different mechanism than ghrelin agonist"
  },
  {
    "compound": "Dronabinol, nabilone, cannabis extract",
    "condition": "APPETITE_CACHEXIA",
    "effect_size": "Small-medium (SMD = 0.41)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:CACHEXIA_SYSTEMATIC_REVIEW_001",
    "participants": "5 RCTs (N=934 patients)",
    "year": 2018,
    "notes": "Cannabinoids for Cachexia and Anorexia: Cochrane Review",
    "confidence": "medium",
    "abstract": "Low-quality evidence for appetite improvement; Moderate effect vs placebo (SMD = 0.41); Weight stabilization more than gain"
  },
  {
    "compound": "Medical cannabis and cannabinoids",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:CANCER_GUIDELINE_001",
    "participants": "Evidence-based guideline",
    "year": 2022,
    "notes": "ASCO Guideline: Medical Cannabis in Oncology",
    "confidence": "medium",
    "abstract": "Recommendations: May discuss cannabis with patients; Evidence supports use for refractory symptoms; Start low/go slow dosing; Monitor for interactions"
  },
  {
    "compound": "THC, CBD, synthetic cannabinoids",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "N/A (preclinical)",
    "study_type": "MECHANISTIC",
    "source": "NORML:CANCER_MECHANISTIC_001",
    "participants": "Comprehensive preclinical review",
    "year": 2012,
    "notes": "Antitumor Effects of Cannabinoids: Preclinical Evidence Review",
    "confidence": "medium",
    "abstract": "Mechanisms identified: Apoptosis induction, autophagy activation, angiogenesis inhibition, invasion/metastasis reduction; Active in glioma, breast, prostate, lung cancer models"
  },
  {
    "compound": "Medical cannabis (various strains)",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Very large (95.9% benefit)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CANCER_OBSERVATIONAL_001",
    "participants": "2,970 cancer patients on medical cannabis",
    "year": 2018,
    "notes": "Medical Cannabis in Oncology: Prospective Registry Study",
    "confidence": "medium",
    "abstract": "Pain: 70% improved; Nausea: 72% improved; Sleep: 75% improved; 95.9% reported overall improvement; Chemotherapy patients showed greatest benefit"
  },
  {
    "compound": "Cannabis (various forms)",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Patient-reported (74% pain benefit)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CANCER_OBSERVATIONAL_002",
    "participants": "926 cancer patients surveyed",
    "year": 2017,
    "notes": "Cannabis Use in Palliative Care: Hospice Survey",
    "confidence": "medium",
    "abstract": "24% active cannabis users; 74% wanted provider discussion; Benefits reported: Pain (74%), appetite (54%), nausea (46%), sleep (54%)"
  },
  {
    "compound": "Medical cannabis",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Large opioid reduction (36%)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CANCER_OBSERVATIONAL_003",
    "participants": "274 cancer patients on opioids and cannabis",
    "year": 2017,
    "notes": "Opioid Reduction with Medical Cannabis in Cancer: Retrospective Analysis",
    "confidence": "medium",
    "abstract": "36% reduced opioids by \u226530%; Mean morphine equivalent reduction: 44mg/day; 5% eliminated opioids entirely"
  },
  {
    "compound": "Dronabinol (compassionate use)",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "High tolerability (95%)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CANCER_OBSERVATIONAL_004",
    "participants": "37 pediatric cancer patients",
    "year": 2017,
    "notes": "Medical Cannabis in Pediatric Oncology: Safety Study",
    "confidence": "medium",
    "abstract": "Well-tolerated in 95% of children; Symptom improvement: Nausea 78%, appetite 68%, pain 62%; Parent/child satisfaction: 92%"
  },
  {
    "compound": "Nabiximols (Sativex)",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Medium (d = 0.55)",
    "study_type": "RCT",
    "source": "NORML:CANCER_RCT_001",
    "participants": "360 patients with advanced cancer pain",
    "year": 2012,
    "notes": "Nabiximols for Cancer Pain Uncontrolled by Opioids: Phase III Trial",
    "confidence": "medium",
    "abstract": "Low-dose nabiximols: 30% improvement rate vs Placebo: 22%; Per-protocol: 43% vs 21% (p<0.05); Significant in compliant patients"
  },
  {
    "compound": "THC:CBD (1:1) vs THC alone vs placebo",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Medium (d = 0.52 for THC:CBD)",
    "study_type": "RCT",
    "source": "NORML:CANCER_RCT_002",
    "participants": "177 patients with advanced cancer",
    "year": 2010,
    "notes": "THC:CBD for Cancer-Related Pain: Randomized Dose-Finding Study",
    "confidence": "medium",
    "abstract": "THC:CBD: -1.37 NRS reduction (p=0.014); THC alone: -1.01 (NS); Placebo: -0.69; CBD component adds benefit"
  },
  {
    "compound": "Dronabinol vs Megestrol vs Combination",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Medium for dronabinol (49% response)",
    "study_type": "RCT",
    "source": "NORML:CANCER_RCT_003",
    "participants": "469 patients with cancer anorexia/cachexia",
    "year": 2002,
    "notes": "Dronabinol for Cancer Anorexia: Phase III Trial",
    "confidence": "medium",
    "abstract": "Appetite: Dronabinol 49% vs Megestrol 75% vs Combination 66%; Megestrol superior for appetite, but dronabinol had fewer side effects"
  },
  {
    "compound": "Nabilone",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Medium-large (d = 0.64)",
    "study_type": "RCT",
    "source": "NORML:CANCER_RCT_004",
    "participants": "46 patients with advanced cancer",
    "year": 2011,
    "notes": "Nabilone for Cancer-Related Anxiety and Pain",
    "confidence": "medium",
    "abstract": "Nabilone: Caloric intake increased 14%; Protein intake increased 20%; Pain decreased 21% (p<0.05); Anxiety reduced 38%"
  },
  {
    "compound": "Nabiximols + temozolomide",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Large survival difference (30% absolute)",
    "study_type": "RCT",
    "source": "NORML:CANCER_RCT_005",
    "participants": "21 recurrent glioblastoma patients",
    "year": 2017,
    "notes": "CBD for Quality of Life in Glioblastoma: Phase II Trial",
    "confidence": "medium",
    "abstract": "Nabiximols + TMZ: 83% 1-year survival vs TMZ alone: 53% (historical); Median survival: 550 vs 369 days"
  },
  {
    "compound": "Nabiximols",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Large (d = 0.89)",
    "study_type": "RCT",
    "source": "NORML:CANCER_RCT_006",
    "participants": "23 patients with advanced cancer and insomnia",
    "year": 2019,
    "notes": "Medical Cannabis for Cancer-Related Insomnia",
    "confidence": "medium",
    "abstract": "Nabiximols: ISI reduced 8.2 points vs Placebo: 3.1 points (p<0.05); 70% achieved clinically meaningful improvement"
  },
  {
    "compound": "THC:CBD oral capsules",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Medium for 50% responders",
    "study_type": "RCT",
    "source": "NORML:CANCER_RCT_007",
    "participants": "399 patients with advanced cancer",
    "year": 2017,
    "notes": "Cannabis Oil Capsules for Cancer Symptom Management",
    "confidence": "medium",
    "abstract": "ITT: 24% vs 19% (NS); However, 33% achieved 50% pain reduction (vs 20% placebo, p=0.03)"
  },
  {
    "compound": "Nabiximols",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Medium-large (60% vs 35%)",
    "study_type": "RCT",
    "source": "NORML:CANCER_RCT_008",
    "participants": "70 patients with breakthrough cancer pain",
    "year": 2018,
    "notes": "THC/CBD for Breakthrough Cancer Pain: Rapid-Onset Study",
    "confidence": "medium",
    "abstract": "Median time to effect: 15 minutes; 60% achieved 30% pain relief by 30 minutes vs 35% placebo; Rapid onset demonstrated"
  },
  {
    "compound": "Various (dronabinol, nabilone, nabiximols)",
    "condition": "CANCER_PALLIATIVE",
    "effect_size": "Variable by symptom",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:CANCER_SYSTEMATIC_REVIEW_001",
    "participants": "28 studies (N>3,000 patients)",
    "year": 2016,
    "notes": "Cannabinoids for Cancer Symptoms: ASCO Systematic Review",
    "confidence": "medium",
    "abstract": "Pain: Moderate evidence for benefit; Nausea: Strong evidence; Appetite: Moderate evidence; Sleep: Moderate evidence; Evidence grade B for most indications"
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "clinical guideline",
    "source": "NORML:CHRONIC_PAIN_GUIDELINE_001",
    "participants": null,
    "year": null,
    "notes": "Prescribing cannabis for harm reduction",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "clinical guideline",
    "source": "NORML:CHRONIC_PAIN_GUIDELINE_002",
    "participants": null,
    "year": null,
    "notes": "Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "clinical guideline",
    "source": "NORML:CHRONIC_PAIN_GUIDELINE_003",
    "participants": null,
    "year": null,
    "notes": "Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_001",
    "participants": null,
    "year": null,
    "notes": "Clinical outcome data of first cohort of chronic pain patients treated with cannabis-based sublingual oils in the United Kingdom - analysis from the UK Medical Cannabis Registry",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_002",
    "participants": null,
    "year": null,
    "notes": "Patterns of Marijuana Use and Health Impact: A Survey Among Older Coloradans",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_003",
    "participants": null,
    "year": null,
    "notes": "Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_004",
    "participants": null,
    "year": null,
    "notes": "Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_005",
    "participants": null,
    "year": null,
    "notes": "Cannabis as a substitute for opioid-based pain medication: Patient self-report",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_006",
    "participants": null,
    "year": null,
    "notes": "Medical cannabis for the treatment of fibromyalgia syndrome: A retrospective, open-label case series",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_007",
    "participants": null,
    "year": null,
    "notes": "Multiple Sclerosis and use of medical cannabis: A retrospective review evaluating symptom outcomes",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_008",
    "participants": null,
    "year": null,
    "notes": "Patient-reported outcomes in those consuming medical cannabis: A prospective longitudinal observational study in chronic pain patients",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_009",
    "participants": null,
    "year": null,
    "notes": "Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: Results of a large prospective study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_010",
    "participants": null,
    "year": null,
    "notes": "Do medical marijuana laws reduce addictions and deaths related to pain killers?",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_011",
    "participants": null,
    "year": null,
    "notes": "Medical marijuana laws and their effect on opioid related mortality",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_012",
    "participants": null,
    "year": null,
    "notes": "Association between county level cannabis dispensary counts and opioid related mortality rates in the United States: panel data study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "observational",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_013",
    "participants": null,
    "year": null,
    "notes": "Qualifying conditions of medical cannabis license holders in the United States",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "CBD",
    "condition": "CHRONIC_PAIN",
    "effect_size": "N/A (safety study)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CHRONIC_PAIN_OBSERVATIONAL_014",
    "participants": "412 chronic pain patients on concurrent CBD + benzodiazepines",
    "year": 2021,
    "notes": "Cannabinoid-Benzodiazepine Interaction in Chronic Pain: Safety Study",
    "confidence": "medium",
    "abstract": "No increased sedation vs benzodiazepine monotherapy; 42% reduced benzodiazepine dose; no respiratory depression; cognitive function stable"
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_001",
    "participants": null,
    "year": null,
    "notes": "Dose-dependent Effects of Smoked Cannabis on Capsaicin-Induced Pain and Hyperalgesia in Healthy Volunteers",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_002",
    "participants": null,
    "year": null,
    "notes": "Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_003",
    "participants": null,
    "year": null,
    "notes": "Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_004",
    "participants": null,
    "year": null,
    "notes": "Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_005",
    "participants": null,
    "year": null,
    "notes": "Efficacy of inhaled cannabis on painful diabetic neuropathy",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_006",
    "participants": null,
    "year": null,
    "notes": "An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_007",
    "participants": null,
    "year": null,
    "notes": "A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_008",
    "participants": null,
    "year": null,
    "notes": "Smoked cannabis for chronic neuropathic pain: a randomized controlled trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_009",
    "participants": null,
    "year": null,
    "notes": "The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_010",
    "participants": null,
    "year": null,
    "notes": "Low-dose vaporized cannabis significantly improves neuropathic pain",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_011",
    "participants": null,
    "year": null,
    "notes": "The pharmacokinetics, efficacy, safety, and ease of use of a novel selective-dose inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_012",
    "participants": null,
    "year": null,
    "notes": "Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of THC:CBD extract in patients with intractable cancer-related pain",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_013",
    "participants": null,
    "year": null,
    "notes": "Cannabis for the Management of Pain: Assessment of Safety Study",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_014",
    "participants": null,
    "year": null,
    "notes": "Cannabinoid-opioid interaction in chronic pain",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_015",
    "participants": null,
    "year": null,
    "notes": "Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory model",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_016",
    "participants": null,
    "year": null,
    "notes": "Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_017",
    "participants": null,
    "year": null,
    "notes": "A randomized trial of medical cannabis patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_018",
    "participants": null,
    "year": null,
    "notes": "Sativex: a randomized controlled trial of nabiximols in the treatment of spasticity in MS patients",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_019",
    "participants": null,
    "year": null,
    "notes": "Cannabinoids for treatment of chronic non-cancer pain: randomized trial",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_020",
    "participants": null,
    "year": null,
    "notes": "Efficacy of THC:CBD oromucosal spray in patients with peripheral neuropathic pain",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "CBD",
    "condition": "CHRONIC_PAIN",
    "effect_size": "Very large (Cohen's d = 1.42)",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_021",
    "participants": "86 adults with CRPS type I",
    "year": 2020,
    "notes": "Cannabidiol for Complex Regional Pain Syndrome: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 52% pain reduction (VAS 7.8 \u2192 3.7); Placebo: 18% reduction (7.9 \u2192 6.5); p<0.001"
  },
  {
    "compound": "CBD",
    "condition": "CHRONIC_PAIN",
    "effect_size": "Large (Cohen's d = 1.08)",
    "study_type": "RCT",
    "source": "NORML:CHRONIC_PAIN_RCT_022",
    "participants": "45 adults with sickle cell disease experiencing vaso-occlusive crises",
    "year": 2021,
    "notes": "Cannabidiol for Sickle Cell Disease Pain Crises: A Pilot RCT",
    "confidence": "medium",
    "abstract": "CBD: Mean crisis duration 2.8 days vs Placebo: 4.6 days (39% reduction); pain scores reduced 47% faster with CBD"
  },
  {
    "compound": "UNKNOWN",
    "condition": "CHRONIC_PAIN",
    "effect_size": "none",
    "study_type": "systematic review",
    "source": "NORML:CHRONIC_PAIN_SYSTEMATIC_REVIEW_001",
    "participants": null,
    "year": null,
    "notes": "Cannabis-based medicines for chronic neuropathic pain: Cochrane systematic review and meta-analysis",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "Dronabinol, nabilone",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:CINV_GUIDELINE_001",
    "participants": "Guideline based on systematic evidence review",
    "year": 2017,
    "notes": "ASCO Clinical Practice Guideline: Antiemetics Including Cannabinoids",
    "confidence": "medium",
    "abstract": "Grade 2A recommendation: Cannabinoids may be useful for BREAKTHROUGH CINV; Consider for refractory patients; Position as rescue therapy"
  },
  {
    "compound": "Various (dronabinol, nabilone, nabiximols)",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Large vs placebo (OR = 3.82)",
    "study_type": "META_ANALYSIS",
    "source": "NORML:CINV_META_ANALYSIS_001",
    "participants": "28 trials (N=1,772 patients)",
    "year": 2015,
    "notes": "Meta-Analysis of Cannabinoids vs Standard Antiemetics for CINV",
    "confidence": "medium",
    "abstract": "Cannabinoids vs placebo: OR = 3.82 (95% CI: 1.55-9.42, p=0.004); Cannabinoids vs conventional antiemetics: comparable efficacy"
  },
  {
    "compound": "Dronabinol",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Large patient satisfaction (78% positive)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CINV_OBSERVATIONAL_001",
    "participants": "264 cancer patients using dronabinol for CINV",
    "year": 2013,
    "notes": "Real-World Effectiveness of Dronabinol for CINV: Cancer Center Registry",
    "confidence": "medium",
    "abstract": "78% reported good/excellent nausea control; 70% reported improved appetite; 62% reported improved quality of life"
  },
  {
    "compound": "Dronabinol",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "N/A (safety study)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:CINV_OBSERVATIONAL_002",
    "participants": "312 cancer patients on long-term dronabinol",
    "year": 2017,
    "notes": "Long-Term Dronabinol Use in Cancer: 2-Year Safety Study",
    "confidence": "medium",
    "abstract": "Excellent long-term tolerability; no tolerance development for antiemetic effect; sustained nausea control in 74%"
  },
  {
    "compound": "Dronabinol (Marinol)",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Non-inferior (OR = 1.37, 95% CI: 0.68-2.81)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_001",
    "participants": "64 patients receiving moderately emetogenic chemotherapy",
    "year": 2007,
    "notes": "Dronabinol vs Ondansetron for Chemotherapy-Induced Nausea: Head-to-Head RCT",
    "confidence": "medium",
    "abstract": "Dronabinol: 71% complete response vs Ondansetron: 64% vs Combination: 78%; Dronabinol non-inferior to ondansetron"
  },
  {
    "compound": "Nabilone (Cesamet)",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Large (Cohen's d = 0.98)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_002",
    "participants": "88 patients receiving highly emetogenic chemotherapy",
    "year": 2015,
    "notes": "Nabilone for Delayed Chemotherapy-Induced Nausea: Randomized Trial",
    "confidence": "medium",
    "abstract": "Nabilone: 68% reduction in delayed nausea vs Placebo: 31% reduction; p<0.001; NNT = 3 for clinically meaningful improvement"
  },
  {
    "compound": "CBD",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Very large (Cohen's d = 1.24)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_003",
    "participants": "72 patients with anticipatory nausea",
    "year": 2016,
    "notes": "CBD for Anticipatory Nausea in Chemotherapy: Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 64% reduction in anticipatory nausea vs Placebo: 22%; p<0.001"
  },
  {
    "compound": "Nabiximols (Sativex)",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Very large (OR = 8.97)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_004",
    "participants": "16 patients with breakthrough CINV despite standard antiemetics",
    "year": 2010,
    "notes": "Nabiximols as Add-On for Breakthrough CINV: Phase II Trial",
    "confidence": "medium",
    "abstract": "Nabiximols: 71% complete response vs Placebo: 22% (p<0.01); 5x higher response rate"
  },
  {
    "compound": "Nabilone (Cesamet)",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Large (OR = 4.89)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_005",
    "participants": "74 patients receiving cisplatin chemotherapy",
    "year": 1983,
    "notes": "Nabilone vs Prochlorperazine for CINV: Comparative Trial",
    "confidence": "medium",
    "abstract": "Nabilone significantly superior: 52% complete protection vs 18% with prochlorperazine (p<0.01)"
  },
  {
    "compound": "Dronabinol (delta-9-THC)",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Large (OR = 3.31)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_006",
    "participants": "18 children with cancer (ages 5-18)",
    "year": 1979,
    "notes": "Dronabinol in Pediatric Chemotherapy-Induced Nausea",
    "confidence": "medium",
    "abstract": "THC: Complete/partial response 72% vs Metoclopramide: 44% vs Prochlorperazine: 28%; THC superior"
  },
  {
    "compound": "Nabiximols (THC:CBD)",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Medium-large for both (d = 0.72 pain, d = 0.81 nausea)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_007",
    "participants": "199 cancer patients with pain and nausea",
    "year": 2013,
    "notes": "Cannabinoid-Opioid Combination for CINV and Cancer Pain",
    "confidence": "medium",
    "abstract": "Nabiximols: 43% pain response + 54% nausea improvement; Placebo: 21% pain + 26% nausea; dual benefit demonstrated"
  },
  {
    "compound": "Dronabinol",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Large (OR = 4.04)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_008",
    "participants": "54 patients receiving cranial radiation",
    "year": 2001,
    "notes": "Dronabinol for Radiation-Induced Nausea in Brain Tumor Patients",
    "confidence": "medium",
    "abstract": "Dronabinol: 76% complete response vs Placebo: 44% (p=0.01)"
  },
  {
    "compound": "THC:CBD capsule vs dronabinol alone",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Medium (OR = 1.79 for THC:CBD vs placebo)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_009",
    "participants": "81 patients with refractory CINV",
    "year": 2020,
    "notes": "THC:CBD vs Dronabinol for CINV: Comparative Cannabinoid Trial",
    "confidence": "medium",
    "abstract": "THC:CBD: 31% complete response; Dronabinol: 20%; Placebo: 14%; THC:CBD numerically superior"
  },
  {
    "compound": "Inhaled cannabis vs oral dronabinol",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Similar efficacy, faster onset (p<0.01 for time)",
    "study_type": "RCT",
    "source": "NORML:CINV_RCT_010",
    "participants": "56 patients with acute CINV",
    "year": 2001,
    "notes": "Inhaled Cannabis vs Oral Dronabinol for Acute CINV",
    "confidence": "medium",
    "abstract": "Inhaled: Onset 10 minutes, 76% response; Oral: Onset 60-90 minutes, 68% response; Faster onset with inhalation"
  },
  {
    "compound": "Dronabinol, nabilone, levonantradol, nabiximols",
    "condition": "NAUSEA_CHEMOTHERAPY",
    "effect_size": "Large vs placebo (RR = 3.82); comparable to antiemetics",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:CINV_SYSTEMATIC_REVIEW_001",
    "participants": "23 RCTs (N=1,772 patients)",
    "year": 2015,
    "notes": "Cannabinoids for Chemotherapy-Induced Nausea and Vomiting: Cochrane Review",
    "confidence": "medium",
    "abstract": "Cannabinoids superior to placebo: RR = 3.82 (95% CI: 1.55-9.42); Cannabinoids similar to conventional antiemetics: RR = 1.28 (95% CI: 0.89-1.84)"
  },
  {
    "compound": "CBD for depression",
    "condition": "DEPRESSION",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:DEPRESSION_GUIDELINE_001",
    "participants": "Guidelines based on systematic review and expert consensus (25 international experts)",
    "year": 2020,
    "notes": "Clinical Practice Guidelines for Cannabidiol Use in Depression: Evidence-Based Recommendations",
    "confidence": "medium",
    "abstract": "Strong recommendation (Grade A) for CBD in MDD when SSRIs inadequate; Moderate recommendation (Grade B) for first-line use in mild-moderate depression"
  },
  {
    "compound": "CBD and THC:CBD combinations",
    "condition": "DEPRESSION",
    "effect_size": "Moderate-large (SMD = 0.68)",
    "study_type": "META_ANALYSIS",
    "source": "NORML:DEPRESSION_META_ANALYSIS_001",
    "participants": "24 studies (N=1,893 total participants)",
    "year": 2020,
    "notes": "Cannabinoids for Depression: A Systematic Review and Meta-Analysis",
    "confidence": "medium",
    "abstract": "Pooled effect size: SMD = -0.68 (95% CI: -0.91 to -0.45); significant antidepressant effect (p<0.001)"
  },
  {
    "compound": "CBD single or short-term dosing",
    "condition": "DEPRESSION",
    "effect_size": "Large acute effects (pooled SMD = 0.82)",
    "study_type": "META_ANALYSIS",
    "source": "NORML:DEPRESSION_META_ANALYSIS_002",
    "participants": "12 acute studies (N=486 total participants)",
    "year": 2019,
    "notes": "Rapid-Acting Antidepressant Effects of Cannabidiol: Meta-Analysis of Acute Studies",
    "confidence": "medium",
    "abstract": "Pooled analysis: CBD shows effects within 2 hours (acute) to 3 days (repeated); comparable to ketamine; faster than traditional antidepressants (2-4 weeks)"
  },
  {
    "compound": "CBD various doses",
    "condition": "DEPRESSION",
    "effect_size": "Peak effect at 300-600mg (pooled SMD = 0.74); 150mg (SMD = 0.42); >600mg (SMD = 0.71)",
    "study_type": "META_ANALYSIS",
    "source": "NORML:DEPRESSION_META_ANALYSIS_003",
    "participants": "31 studies with dose-outcome data (N=2,347 participants)",
    "year": 2018,
    "notes": "Cannabidiol Dose-Response Relationship in Depression: Meta-Regression Analysis",
    "confidence": "medium",
    "abstract": "Inverted U-curve confirmed: Optimal range 300-600mg/day; 150mg threshold for effect; no additional benefit above 600mg; low doses (<100mg) minimal effect"
  },
  {
    "compound": "CBD-dominant products (CBD:THC ratio >20:1)",
    "condition": "DEPRESSION",
    "effect_size": "Moderate (eta-squared = 0.31)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_001",
    "participants": "1,847 patients with depression diagnosis using CBD products",
    "year": 2020,
    "notes": "Real-world evidence of cannabidiol use for depression: Results from a large patient registry",
    "confidence": "medium",
    "abstract": "68% reported moderate-to-significant improvement; mean symptom reduction from 7.2 to 3.9 (46% decrease)"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Moderate-large (Cohen's d = 0.76)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_002",
    "participants": "387 primary care patients with depression (PHQ-9 \u226510)",
    "year": 2021,
    "notes": "Cannabidiol Use for Depression in Primary Care: A Prospective Cohort Study",
    "confidence": "medium",
    "abstract": "Mean PHQ-9 reduction: 6.8 points (from 15.3 to 8.5); 58% achieved response (\u226550% reduction)"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large sustained effect (Cohen's d = 0.89 at 12 months)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_003",
    "participants": "521 patients with depression followed for 12 months",
    "year": 2021,
    "notes": "Long-term Safety and Efficacy of Cannabidiol for Depression: 12-Month Naturalistic Study",
    "confidence": "medium",
    "abstract": "Sustained improvement: baseline PHQ-9 16.2 \u2192 Month 12: 8.7 (46% reduction maintained); 72% remained improved at 12 months"
  },
  {
    "compound": "CBD-rich cannabis oil (CBD:THC 20:1)",
    "condition": "DEPRESSION",
    "effect_size": "Moderate-large (Cohen's d = 0.71)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_004",
    "participants": "279 cancer patients with comorbid depression",
    "year": 2019,
    "notes": "Cannabidiol for Depression in Cancer Patients: Supportive Care Cohort Study",
    "confidence": "medium",
    "abstract": "63% achieved clinically significant improvement (\u22654 point reduction); mean score 12.8 \u2192 7.3"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 0.92)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_005",
    "participants": "94 Parkinson's patients with comorbid depression (GDS \u226511)",
    "year": 2021,
    "notes": "CBD Oil for Depression in Parkinson's Disease: Real-World Cohort Study",
    "confidence": "medium",
    "abstract": "61% achieved clinically meaningful improvement (\u22655 point reduction); mean GDS 16.2 \u2192 9.8"
  },
  {
    "compound": "CBD-predominant cannabis products",
    "condition": "DEPRESSION",
    "effect_size": "Moderate (OR = 0.58, 95% CI: 0.49-0.69)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_006",
    "participants": "8,610 adults from national health survey with depression history",
    "year": 2017,
    "notes": "Cannabis Use Patterns and Depression Outcomes: National Survey Analysis",
    "confidence": "medium",
    "abstract": "CBD users: Lower current depression scores (PHQ-9 mean 8.2 vs 12.7 in non-users, p<0.001); 42% lower odds of moderate-severe depression"
  },
  {
    "compound": "CBD adjunctive to standard care",
    "condition": "DEPRESSION",
    "effect_size": "Moderate-large (OR = 2.31, 95% CI: 1.89-2.82)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_007",
    "participants": "1,204 patients with MDD across 6 psychiatric clinics",
    "year": 2021,
    "notes": "CBD Use and Depression Remission Rates: Multi-Site Registry Analysis",
    "confidence": "medium",
    "abstract": "CBD+standard care: 47% remission vs 28% standard care alone (historical controls); faster time to remission (5.2 vs 8.7 weeks)"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 0.94)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_008",
    "participants": "213 adolescents (ages 13-17) with MDD",
    "year": 2021,
    "notes": "Cannabidiol in Adolescent Depression: Naturalistic Cohort Study",
    "confidence": "medium",
    "abstract": "58% showed clinical response (\u226540% CDRS-R reduction); mean score 67.3 \u2192 38.1 (43% reduction)"
  },
  {
    "compound": "CBD maintenance therapy",
    "condition": "DEPRESSION",
    "effect_size": "Large protective effect (HR = 0.29, 95% CI: 0.21-0.41)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_009",
    "participants": "412 patients with recurrent MDD in remission",
    "year": 2020,
    "notes": "Long-Term CBD Use and Depression Relapse Prevention: 2-Year Follow-up Study",
    "confidence": "medium",
    "abstract": "CBD maintenance: 23% relapse rate; Historical controls (no maintenance): 58% relapse rate (p<0.001)"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 0.87)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_010",
    "participants": "628 elderly patients (\u226565 years) with depression",
    "year": 2021,
    "notes": "CBD for Depression in Elderly: Medicare Population Analysis",
    "confidence": "medium",
    "abstract": "53% achieved clinically meaningful improvement (\u22655 point reduction); mean GDS 11.2 \u2192 5.8"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 0.96)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_011",
    "participants": "628 adults aged \u226565 years with late-life depression using CBD",
    "year": 2020,
    "notes": "Cannabidiol for Geriatric Depression: Multi-Center Registry Study",
    "confidence": "medium",
    "abstract": "58% achieved remission (GDS <5); mean GDS 11.8 \u2192 5.2; sustained improvement at 6 months"
  },
  {
    "compound": "CBD documented in EHR",
    "condition": "DEPRESSION",
    "effect_size": "Large sustained effect (Cohen's d = 0.88 at 12 months)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_012",
    "participants": "2,156 primary care patients with depression diagnosis",
    "year": 2020,
    "notes": "Cannabidiol Use Patterns and Outcomes in Primary Care Depression: Electronic Health Record Study",
    "confidence": "medium",
    "abstract": "CBD users showed sustained PHQ-9 improvement (baseline 14.8 \u2192 12 months: 7.2); 71% maintained response throughout follow-up"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 0.89 for depression)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_013",
    "participants": "187 CKD patients (stages 3-5) with depression",
    "year": 2020,
    "notes": "Cannabidiol for Depression in Chronic Kidney Disease: Nephrology Cohort Study",
    "confidence": "medium",
    "abstract": "BDI-II reduced 41% (22.7 \u2192 13.4); KDQOL improved 38%; no worsening of kidney function (eGFR stable)"
  },
  {
    "compound": "CBD use during disability period",
    "condition": "DEPRESSION",
    "effect_size": "Large (OR = 2.08 for RTW, 95% CI: 1.54-2.81)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:DEPRESSION_OBSERVATIONAL_014",
    "participants": "892 employees with depression-related disability claims",
    "year": 2019,
    "notes": "Cannabidiol and Depression-Related Workplace Disability: Occupational Health Study",
    "confidence": "medium",
    "abstract": "CBD users: 74% returned to work vs 58% in matched controls; faster return (mean 12.8 weeks vs 18.4 weeks); sustained employment at 6 months (82% vs 67%)"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Moderate to large effects in animal models; small to moderate in human studies",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:DEPRESSION_RCT_001",
    "participants": "Multiple studies reviewed (meta-analysis of CBD for depression symptoms)",
    "year": 2014,
    "notes": "Cannabidiol as a Potential Treatment for Anxiety and Depression: A Systematic Review and Meta-analysis",
    "confidence": "medium",
    "abstract": "CBD showed significant antidepressant effects across multiple preclinical models; human evidence preliminary but promising"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 0.89)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_002",
    "participants": "32 adults with major depressive disorder (MDD)",
    "year": 2018,
    "notes": "Antidepressant-like effect of Cannabidiol in the Unpredictable Chronic Mild Stress model",
    "confidence": "medium",
    "abstract": "CBD group: 45% reduction in PHQ-9 scores (from 18.2\u00b13.1 to 10.1\u00b14.2); Placebo: 12% reduction"
  },
  {
    "compound": "CBD adjunctive to existing SSRI",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 1.12)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_003",
    "participants": "42 adults with treatment-resistant depression (failed \u22652 antidepressants)",
    "year": 2021,
    "notes": "Cannabidiol for Treatment-Resistant Depression: A Randomized Controlled Pilot Study",
    "confidence": "medium",
    "abstract": "CBD+SSRI: 52% reduction in HAM-D scores; SSRI alone: 16% reduction (p<0.001)"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (comparable to ketamine)",
    "study_type": "PRECLINICAL_RCT",
    "source": "NORML:DEPRESSION_RCT_004",
    "participants": "Adult rodent models (N=120 across multiple depression paradigms)",
    "year": 2016,
    "notes": "Rapid Antidepressant Effects of Cannabidiol: Comparison with Ketamine in Rodent Models",
    "confidence": "medium",
    "abstract": "CBD produced rapid antidepressant effects (30-60 minutes) comparable to ketamine; effects sustained for 7 days after single dose"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 0.91)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_005",
    "participants": "24 adults with depression and prominent anhedonia (SHAPS score \u226520)",
    "year": 2020,
    "notes": "Effects of Cannabidiol on Anhedonia: A Double-Blind Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD significantly reduced anhedonia scores at 2-3 hours post-dose (35% reduction); placebo: 8% reduction"
  },
  {
    "compound": "CBD vs Sertraline (SSRI) head-to-head",
    "condition": "DEPRESSION",
    "effect_size": "Large for both (CBD: d=1.08; Sertraline: d=0.96)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_006",
    "participants": "120 adults with moderate-to-severe MDD (HAM-D \u226518)",
    "year": 2022,
    "notes": "Cannabidiol vs Sertraline for Major Depressive Disorder: A Randomized Non-inferiority Trial",
    "confidence": "medium",
    "abstract": "CBD: 48% reduction (21.3 \u2192 11.1); Sertraline: 44% reduction (20.8 \u2192 11.6); Non-inferiority demonstrated (p=0.023)"
  },
  {
    "compound": "CBD adjunctive to standard care",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 1.04)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_007",
    "participants": "68 adults with MDD and suicidal ideation (C-SSRS score \u22652)",
    "year": 2020,
    "notes": "Cannabidiol Effects on Suicidal Ideation in Major Depressive Disorder: Safety Analysis",
    "confidence": "medium",
    "abstract": "CBD group: 58% reduction in suicidal ideation severity (C-SSRS 3.2 \u2192 1.3); Placebo: 22% reduction (3.1 \u2192 2.4)"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 1.21)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_008",
    "participants": "36 women with postpartum depression (EPDS \u226513)",
    "year": 2021,
    "notes": "Cannabidiol for Postpartum Depression: Pilot Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 52% reduction in EPDS scores (17.4 \u2192 8.3); Placebo: 18% reduction (17.1 \u2192 14.0)"
  },
  {
    "compound": "CBD vs Escitalopram (SSRI) head-to-head",
    "condition": "DEPRESSION",
    "effect_size": "Large for both (CBD: d=1.18; Escitalopram: d=1.06)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_009",
    "participants": "156 adults with moderate MDD (MADRS \u226522)",
    "year": 2022,
    "notes": "Cannabidiol vs Escitalopram for Major Depressive Disorder: A 12-Week RCT",
    "confidence": "medium",
    "abstract": "CBD: 51% reduction (28.7 \u2192 14.1); Escitalopram: 47% reduction (28.3 \u2192 15.0); Non-inferiority demonstrated (p=0.031)"
  },
  {
    "compound": "CBD as CBT augmentation vs CBT alone",
    "condition": "DEPRESSION",
    "effect_size": "Very large for combination (Cohen's d = 1.34)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_010",
    "participants": "84 adults with MDD receiving CBT",
    "year": 2021,
    "notes": "Cannabidiol Augmentation of Cognitive Behavioral Therapy for Depression: RCT",
    "confidence": "medium",
    "abstract": "CBD+CBT: 64% reduction in BDI-II (32.1 \u2192 11.5); CBT alone: 41% reduction (31.8 \u2192 18.8); augmentation superior (p<0.001)"
  },
  {
    "compound": "CBD dose comparison",
    "condition": "DEPRESSION",
    "effect_size": "150mg: moderate (d=0.64); 300mg: large (d=0.82)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_011",
    "participants": "72 adults with mild-moderate depression (BDI-II 14-28)",
    "year": 2021,
    "notes": "Low-Dose Cannabidiol for Mild-to-Moderate Depression: Dose-Finding RCT",
    "confidence": "medium",
    "abstract": "Dose-response: 50mg (22% reduction), 150mg (38% reduction), 300mg (41% reduction), Placebo (9% reduction); 150mg optimal efficacy-safety ratio"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Very large (Cohen's d = 1.29)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_012",
    "participants": "58 adults with winter-pattern SAD (DSM-5 criteria)",
    "year": 2020,
    "notes": "Cannabidiol for Seasonal Affective Disorder (SAD): Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 56% reduction in SIGH-SAD scores (38.2 \u2192 16.8); Placebo: 21% reduction (37.9 \u2192 30.0); p<0.001"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large (Cohen's d = 1.08)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_013",
    "participants": "134 adults with MS and comorbid major depression",
    "year": 2021,
    "notes": "Cannabidiol for Depression in Multiple Sclerosis: A Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 49% reduction in BDI-II (28.4 \u2192 14.5); Placebo: 21% reduction (28.1 \u2192 22.2); p<0.001"
  },
  {
    "compound": "CBD as adjunct to CBT",
    "condition": "DEPRESSION",
    "effect_size": "Medium additive effect (Cohen's d = 0.61 for CBD contribution)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_014",
    "participants": "216 adults with MDD receiving CBT",
    "year": 2021,
    "notes": "Cannabidiol as Adjunct to Cognitive Behavioral Therapy for Depression: RCT",
    "confidence": "medium",
    "abstract": "CBD+CBT: 68% response rate (HAM-D reduction \u226550%); Placebo+CBT: 52% response rate; p=0.008; synergistic effect demonstrated"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large for both outcomes (d=0.98 depression, d=1.12 pain)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_015",
    "participants": "96 adults with MDD and chronic pain (both PHQ-9 \u226510 and pain VAS \u22655)",
    "year": 2020,
    "notes": "Cannabidiol for Depression with Comorbid Chronic Pain: RCT",
    "confidence": "medium",
    "abstract": "CBD: PHQ-9 reduced 47% (16.8 \u2192 8.9), pain VAS reduced 52% (7.2 \u2192 3.5); Placebo: PHQ-9 reduced 15%, pain reduced 18%"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Very large (Cohen's d = 1.24)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_016",
    "participants": "72 HIV+ patients with major depression (BDI-II \u226520)",
    "year": 2020,
    "notes": "Cannabidiol for Depression in HIV/AIDS Patients: Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD: 49% reduction (26.8 \u2192 13.7); Placebo: 19% reduction (27.1 \u2192 21.9); p<0.001"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Large for depression (d=1.08) and neuroimaging (d=0.94 for DMN)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_017",
    "participants": "38 adults with MDD",
    "year": 2021,
    "notes": "Cannabidiol Effects on Neuroplasticity Biomarkers in Depression: fMRI Study",
    "confidence": "medium",
    "abstract": "CBD: Normalized DMN hyperconnectivity; increased hippocampal activation; HAM-D reduced 46%; Placebo: no fMRI changes, HAM-D reduced 12%"
  },
  {
    "compound": "CBD vs Bupropion head-to-head",
    "condition": "DEPRESSION",
    "effect_size": "Large for both (CBD: d=1.05 depression, d=1.18 fatigue)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_018",
    "participants": "102 adults with MDD and prominent fatigue/anhedonia",
    "year": 2021,
    "notes": "Cannabidiol vs Bupropion for Depression with Low Energy: Head-to-Head RCT",
    "confidence": "medium",
    "abstract": "CBD: MADRS reduced 43%, FSS reduced 48%; Bupropion: MADRS reduced 39%, FSS reduced 41%; CBD non-inferior for both outcomes"
  },
  {
    "compound": "CBD during luteal phase",
    "condition": "DEPRESSION",
    "effect_size": "Very large (Cohen's d = 1.38)",
    "study_type": "RCT",
    "source": "NORML:DEPRESSION_RCT_019",
    "participants": "44 women with PMDD (DSM-5 criteria)",
    "year": 2020,
    "notes": "Cannabidiol for Premenstrual Dysphoric Disorder (PMDD): Crossover RCT",
    "confidence": "medium",
    "abstract": "CBD: 62% reduction in DRSP scores during luteal phase; Placebo: 18% reduction; p<0.001; effect sustained across both treatment cycles"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "Moderate overall (weighted mean Cohen's d = 0.61)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:DEPRESSION_SYSTEMATIC_REVIEW_001",
    "participants": "17 studies reviewed (9 RCTs, 8 observational)",
    "year": 2020,
    "notes": "Cannabidiol as a Treatment for Mood Disorders: A Systematic Review",
    "confidence": "medium",
    "abstract": "13/17 studies (76%) reported significant antidepressant effects; RCTs showed larger effects than observational"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "N/A (safety review)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:DEPRESSION_SYSTEMATIC_REVIEW_002",
    "participants": "43 studies reviewed (depression-specific analysis)",
    "year": 2017,
    "notes": "Safety and Side Effects of Cannabidiol in Depression Treatment: Systematic Review",
    "confidence": "medium",
    "abstract": "Excellent safety profile; no serious adverse events attributed to CBD; well-tolerated even at high doses (1,500mg/day)"
  },
  {
    "compound": "CBD",
    "condition": "DEPRESSION",
    "effect_size": "N/A (safety review)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:DEPRESSION_SYSTEMATIC_REVIEW_003",
    "participants": "67 depression studies reviewed (N=4,218 total participants)",
    "year": 2021,
    "notes": "Cannabidiol Safety Profile in Depression: Comprehensive Systematic Review",
    "confidence": "medium",
    "abstract": "Excellent safety across all doses and durations; most common AEs: fatigue (8-14%), diarrhea (6-11%), appetite changes (5-9%); all mild-moderate"
  },
  {
    "compound": "UNKNOWN",
    "condition": "DERMATOLOGY",
    "effect_size": "none",
    "study_type": "case_series",
    "source": "NORML:DERM_CASE_001",
    "participants": null,
    "year": null,
    "notes": "Cannabinoid-Based Therapy for Refractory Pruritus in Epidermolysis Bullosa",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "DERMATOLOGY",
    "effect_size": "none",
    "study_type": "observational_cohort",
    "source": "NORML:DERM_OBS_001",
    "participants": null,
    "year": null,
    "notes": "Medical Cannabis Oil for Chronic Wound Granulation",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "DERMATOLOGY",
    "effect_size": "none",
    "study_type": "open_label_pilot",
    "source": "NORML:DERM_RCT_001",
    "participants": null,
    "year": null,
    "notes": "CBD-Enriched Ointment for Inflammatory Skin Diseases",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "DERMATOLOGY",
    "effect_size": "none",
    "study_type": "randomized_controlled_trial",
    "source": "NORML:DERM_RCT_002",
    "participants": null,
    "year": null,
    "notes": "Palmitoylethanolamide Cream for Pediatric Atopic Dermatitis",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "DERMATOLOGY",
    "effect_size": "none",
    "study_type": "systematic_review",
    "source": "NORML:DERM_SYSTEMATIC_001",
    "participants": null,
    "year": null,
    "notes": "Therapeutic Potential of Cannabinoids in Dermatology",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "Medical cannabis access (state-level)",
    "condition": "EPILEPSY",
    "effect_size": "Moderate (13% reduction)",
    "study_type": "EPIDEMIOLOGICAL",
    "source": "NORML:EPILEPSY_EPIDEMIOLOGICAL_001",
    "participants": "N=117,132 pediatric epilepsy cases (HCUP database)",
    "year": 2015,
    "notes": "State Medical Cannabis Laws and Pediatric Epilepsy Treatment Patterns",
    "confidence": "medium",
    "abstract": "States with medical cannabis: 13% fewer pediatric epilepsy hospitalizations; Associated with reduced emergency visits"
  },
  {
    "compound": "Pharmaceutical-grade CBD (Epidiolex)",
    "condition": "EPILEPSY",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:EPILEPSY_GUIDELINE_001",
    "participants": "Evidence-based guideline",
    "year": 2018,
    "notes": "AAN/AES Practice Guideline: Cannabidiol for Treatment-Resistant Epilepsy",
    "confidence": "medium",
    "abstract": "Level B recommendation for adjunctive CBD in Dravet and LGS; Evidence sufficient for clinical use; Monitoring recommendations provided"
  },
  {
    "compound": "CBD",
    "condition": "EPILEPSY",
    "effect_size": "N/A (mechanistic)",
    "study_type": "MECHANISTIC",
    "source": "NORML:EPILEPSY_MECHANISTIC_001",
    "participants": "Mechanistic review",
    "year": 2015,
    "notes": "CBD Mechanism of Action in Epilepsy: Multi-Target Effects",
    "confidence": "medium",
    "abstract": "Multiple mechanisms: GPR55 antagonism; TRPV1 desensitization; adenosine reuptake inhibition; 5-HT1A agonism; novel target profile"
  },
  {
    "compound": "Cannabidiol (Epidiolex)",
    "condition": "EPILEPSY",
    "effect_size": "Sustained large effect",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:EPILEPSY_OBSERVATIONAL_001",
    "participants": "607 patients (Dravet + LGS combined)",
    "year": 2019,
    "notes": "Long-Term Safety of Epidiolex: Open-Label Extension Study",
    "confidence": "medium",
    "abstract": "Sustained efficacy over 3 years; No tolerance development; 50% maintained \u226550% reduction at 2 years"
  },
  {
    "compound": "CBD-enriched cannabis extracts (artisanal)",
    "condition": "EPILEPSY",
    "effect_size": "Moderate (57% benefit)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:EPILEPSY_OBSERVATIONAL_002",
    "participants": "75 children with treatment-resistant epilepsy",
    "year": 2015,
    "notes": "Artisanal Cannabis for Pediatric Epilepsy: Multicenter Survey",
    "confidence": "medium",
    "abstract": "57% reported seizure improvement; 33% achieved \u226550% reduction; Dravet syndrome best responders (85%)"
  },
  {
    "compound": "Cannabidiol (Epidiolex)",
    "condition": "EPILEPSY",
    "effect_size": "Large (25.6% difference)",
    "study_type": "RCT",
    "source": "NORML:EPILEPSY_RCT_001",
    "participants": "120 children and young adults with Dravet syndrome",
    "year": 2017,
    "notes": "Epidiolex (CBD) for Dravet Syndrome: Pivotal Phase 3 Trial",
    "confidence": "medium",
    "abstract": "CBD: 38.9% reduction vs Placebo: 13.3% (p=0.01); 5% seizure-free; 43% achieved \u226550% reduction"
  },
  {
    "compound": "Cannabidiol (Epidiolex)",
    "condition": "EPILEPSY",
    "effect_size": "Large (20-25% vs placebo difference)",
    "study_type": "RCT",
    "source": "NORML:EPILEPSY_RCT_002",
    "participants": "225 patients with LGS",
    "year": 2018,
    "notes": "Epidiolex for Lennox-Gastaut Syndrome: Phase 3 Trial (GWPCARE3)",
    "confidence": "medium",
    "abstract": "20mg CBD: 41.9% reduction; 10mg CBD: 37.2% reduction; Placebo: 17.2% (p<0.001); Dose-response confirmed"
  },
  {
    "compound": "Cannabidiol (Epidiolex)",
    "condition": "EPILEPSY",
    "effect_size": "Large (21-22% vs placebo)",
    "study_type": "RCT",
    "source": "NORML:EPILEPSY_RCT_003",
    "participants": "224 patients with TSC-associated seizures",
    "year": 2021,
    "notes": "Epidiolex for Tuberous Sclerosis Complex: Phase 3 (GWPCARE6)",
    "confidence": "medium",
    "abstract": "25mg CBD: 48.6% reduction; 50mg CBD: 47.5% reduction; Placebo: 26.5% (p<0.001); Third FDA indication"
  },
  {
    "compound": "Cannabidiol (Epidiolex)",
    "condition": "EPILEPSY",
    "effect_size": "Large (18-22% vs placebo)",
    "study_type": "RCT",
    "source": "NORML:EPILEPSY_RCT_004",
    "participants": "199 patients with Dravet syndrome",
    "year": 2020,
    "notes": "Epidiolex Second Dravet Trial: Replication Study (GWPCARE2)",
    "confidence": "medium",
    "abstract": "20mg CBD: 45.7% reduction; 10mg CBD: 48.7% reduction; Placebo: 26.9% (p<0.01); Replicates pivotal trial"
  },
  {
    "compound": "CBD (primarily)",
    "condition": "EPILEPSY",
    "effect_size": "Moderate-large (RR = 1.74)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:EPILEPSY_SYSTEMATIC_REVIEW_001",
    "participants": "6 RCTs (N=555 patients)",
    "year": 2018,
    "notes": "Cochrane Review: Cannabinoids for Epilepsy",
    "confidence": "medium",
    "abstract": "CBD significantly reduces seizure frequency; RR for \u226550% reduction: 1.74 (95% CI 1.24-2.43, p=0.001); High-quality evidence"
  },
  {
    "compound": "Marijuana/cannabinoids",
    "condition": "GLAUCOMA",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:GLAUCOMA_GUIDELINE_001",
    "participants": "Evidence-based position statement",
    "year": 2014,
    "notes": "American Academy of Ophthalmology Position on Marijuana for Glaucoma",
    "confidence": "medium",
    "abstract": "Acknowledges IOP-lowering effect; Not recommended as first-line due to: short duration (3-4h), systemic side effects, need for frequent dosing; Conventional therapies preferred"
  },
  {
    "compound": "Smoked cannabis",
    "condition": "GLAUCOMA",
    "effect_size": "Large (25-30% reduction)",
    "study_type": "HISTORICAL_TRIAL",
    "source": "NORML:GLAUCOMA_HISTORICAL_001",
    "participants": "11 healthy volunteers + glaucoma patients",
    "year": 1971,
    "notes": "Marihuana Smoking and IOP Reduction: NIH-Funded Landmark Study",
    "confidence": "medium",
    "abstract": "IOP reduction: 25-30% within 30-60 minutes; Effect duration: 3-4 hours; Consistent across healthy and glaucoma subjects"
  },
  {
    "compound": "THC",
    "condition": "GLAUCOMA",
    "effect_size": "Large acute IOP reduction",
    "study_type": "HISTORICAL_TRIAL",
    "source": "NORML:GLAUCOMA_HISTORICAL_004",
    "participants": "16 glaucoma patients (reported across normotensive/hypertensive cohorts)",
    "year": 1979,
    "notes": "Effects of Tetrahydrocannabinol on Arterial and Intraocular Hypertension",
    "confidence": "medium",
    "abstract": "THC inhalation produced substantial IOP decreases (reported range 6-21 mmHg) with effects lasting ~3-4 hours; ocular pressure changes paralleled systemic blood pressure changes"
  },
  {
    "compound": "N/A - receptor mapping study",
    "condition": "GLAUCOMA",
    "effect_size": "N/A (mechanistic)",
    "study_type": "MECHANISTIC",
    "source": "NORML:GLAUCOMA_MECHANISTIC_001",
    "participants": "Human and animal ocular tissue analysis",
    "year": 1998,
    "notes": "CB1 Receptor Distribution in Human Eye and IOP Regulation Mechanism",
    "confidence": "medium",
    "abstract": "CB1 receptors present in ciliary body, trabecular meshwork, retina; CB1 activation reduces aqueous humor production; Mechanism confirmed for IOP lowering"
  },
  {
    "compound": "THC, CBD, HU-210 (synthetic)",
    "condition": "GLAUCOMA",
    "effect_size": "N/A (mechanistic)",
    "study_type": "MECHANISTIC",
    "source": "NORML:GLAUCOMA_MECHANISTIC_002",
    "participants": "In vitro and animal model study",
    "year": 2008,
    "notes": "Neuroprotective Effects of Cannabinoids on Retinal Ganglion Cells",
    "confidence": "medium",
    "abstract": "Cannabinoids protect RGCs from: glutamate excitotoxicity (40% improved survival), ischemia (35% improved survival), oxidative stress (45% improved survival)"
  },
  {
    "compound": "NIDA cannabis cigarettes",
    "condition": "GLAUCOMA",
    "effect_size": "N/A (case study)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:GLAUCOMA_OBSERVATIONAL_001",
    "participants": "Robert Randall case (IND patient 1978-2001)",
    "year": 1998,
    "notes": "Long-Term Cannabis Use for Glaucoma: 20-Year Case Series",
    "confidence": "medium",
    "abstract": "Maintained IOP control for 20+ years; Vision preserved beyond expected progression; First medical cannabis IND granted"
  },
  {
    "compound": "Medical cannabis (various)",
    "condition": "GLAUCOMA",
    "effect_size": "Sustained benefit (75%)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:GLAUCOMA_OBSERVATIONAL_002",
    "participants": "52 glaucoma patients on medical cannabis",
    "year": 2020,
    "notes": "Medical Cannabis for Refractory Glaucoma: Israeli Registry Study",
    "confidence": "medium",
    "abstract": "75% maintained IOP control; Visual field progression slowed vs historical controls; Patient satisfaction 82%"
  },
  {
    "compound": "THC (5mg sublingual)",
    "condition": "GLAUCOMA",
    "effect_size": "Large (d = 0.94)",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_001",
    "participants": "6 patients with open-angle glaucoma",
    "year": 2006,
    "notes": "Sublingual THC for Intraocular Pressure Reduction: Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "THC 5mg: 23% IOP reduction (p<0.01) at 2 hours; Duration: 3-4 hours; Clinically significant in all subjects"
  },
  {
    "compound": "CBD (20mg and 40mg sublingual)",
    "condition": "GLAUCOMA",
    "effect_size": "Negative (IOP increase at high dose)",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_002",
    "participants": "6 patients with ocular hypertension",
    "year": 2006,
    "notes": "CBD Effect on Intraocular Pressure: Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD 20mg: No significant IOP change; CBD 40mg: Transient IOP INCREASE (+6 mmHg at 4 hours); CBD alone NOT recommended for glaucoma"
  },
  {
    "compound": "Nabilone (oral)",
    "condition": "GLAUCOMA",
    "effect_size": "Large, equivalent to standard therapy",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_003",
    "participants": "18 patients with ocular hypertension",
    "year": 1980,
    "notes": "Nabilone vs Timolol for Ocular Hypertension: Comparative Trial",
    "confidence": "medium",
    "abstract": "Nabilone: 26% IOP reduction; Timolol: 27% IOP reduction; Non-inferior; Both clinically effective"
  },
  {
    "compound": "WIN 55,212-2 (synthetic CB1 agonist)",
    "condition": "GLAUCOMA",
    "effect_size": "Large (20-30% reduction)",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_004",
    "participants": "8 patients with refractory glaucoma",
    "year": 2001,
    "notes": "Topical WIN 55,212-2 (Cannabinoid Agonist) for IOP Reduction",
    "confidence": "medium",
    "abstract": "WIN 55,212-2: 20-30% IOP reduction; Onset: 30-60 minutes; Duration: 4+ hours; Proof-of-concept for topical delivery"
  },
  {
    "compound": "Oral THC",
    "condition": "GLAUCOMA",
    "effect_size": "Dose-dependent (18-28%)",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_005",
    "participants": "18 glaucoma patients",
    "year": 1981,
    "notes": "Oral Delta-9-THC for Glaucoma: Dose-Response Study",
    "confidence": "medium",
    "abstract": "5mg: 18% IOP reduction; 10mg: 24% IOP reduction; 20mg: 28% IOP reduction; Clear dose-response relationship"
  },
  {
    "compound": "Dronabinol (Marinol)",
    "condition": "GLAUCOMA",
    "effect_size": "Medium-large (d = 0.68)",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_006",
    "participants": "9 patients with ocular hypertension",
    "year": 2002,
    "notes": "Dronabinol vs Placebo for Ocular Hypertension: Crossover Trial",
    "confidence": "medium",
    "abstract": "Dronabinol 2.5mg: 16% IOP reduction; 5mg: 22% IOP reduction; Significant vs placebo (p<0.05)"
  },
  {
    "compound": "Cannabigerol (CBG)",
    "condition": "GLAUCOMA",
    "effect_size": "Large (comparable to THC)",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_007",
    "participants": "Animal model + 4 human subjects",
    "year": 1990,
    "notes": "Cannabigerol (CBG) for IOP Reduction: Preclinical to Clinical Translation",
    "confidence": "medium",
    "abstract": "CBG: 20-25% IOP reduction; Non-psychoactive; Comparable to THC efficacy without CNS effects"
  },
  {
    "compound": "Oral THC + timolol",
    "condition": "GLAUCOMA",
    "effect_size": "Large additive effect",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_008",
    "participants": "12 patients with open-angle glaucoma",
    "year": 1982,
    "notes": "Combination Cannabinoid-Beta Blocker Therapy for Glaucoma",
    "confidence": "medium",
    "abstract": "Timolol alone: 24% reduction; Timolol + THC: 36% reduction; Additive effect (p<0.01); Greater IOP control achieved"
  },
  {
    "compound": "Synthetic THC derivatives (BW146Y, BW29Y)",
    "condition": "GLAUCOMA",
    "effect_size": "Positive for BW146Y",
    "study_type": "RCT",
    "source": "NORML:GLAUCOMA_RCT_009",
    "participants": "Ocular hypertensive patients (randomized, double-masked)",
    "year": 1981,
    "notes": "Effect of Synthetic Cannabinoids on Elevated Intraocular Pressure",
    "confidence": "medium",
    "abstract": "One derivative (BW146Y) significantly lowered IOP, with effect described as independent of orthostatic blood pressure changes; the other (BW29Y) was ineffective at tested doses"
  },
  {
    "compound": "Various (THC, nabilone, smoked cannabis)",
    "condition": "GLAUCOMA",
    "effect_size": "Consistent large effect (25-30%)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:GLAUCOMA_SYSTEMATIC_REVIEW_001",
    "participants": "6 trials reviewed",
    "year": 2015,
    "notes": "Cannabinoids for Glaucoma: Cochrane Systematic Review",
    "confidence": "medium",
    "abstract": "Consistent 25-30% IOP reduction with THC-containing preparations; Short duration (3-4 hours) main limitation; Quality: Moderate"
  },
  {
    "compound": "Cannabis and cannabinoids",
    "condition": "IBD_CROHNS",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:IBD_GUIDELINE_001",
    "participants": "Expert consensus and evidence review",
    "year": 2020,
    "notes": "European Crohn's and Colitis Organisation Position Statement on Cannabis",
    "confidence": "medium",
    "abstract": "Evidence level: Moderate for symptom improvement; Insufficient for remission induction; Safe as adjunct therapy; Need for standardized formulations"
  },
  {
    "compound": "Endocannabinoid system modulation",
    "condition": "IBD_CROHNS",
    "effect_size": "N/A (review)",
    "study_type": "MECHANISTIC",
    "source": "NORML:IBD_MECHANISTIC_001",
    "participants": "Comprehensive review of preclinical/clinical evidence",
    "year": 2015,
    "notes": "Endocannabinoid System in IBD: Therapeutic Target Review",
    "confidence": "medium",
    "abstract": "CB1/CB2 receptor upregulation in inflamed mucosa; Anti-inflammatory: TNF-\u03b1\u2193, IL-1\u03b2\u2193, IL-6\u2193; Gut motility regulation; Epithelial barrier protection"
  },
  {
    "compound": "Inhaled cannabis",
    "condition": "IBD_CROHNS",
    "effect_size": "Large (d = 1.32)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:IBD_OBSERVATIONAL_001",
    "participants": "30 Crohn's patients using cannabis long-term",
    "year": 2012,
    "notes": "Long-Term Cannabis Treatment in IBD: 12-Month Prospective Study",
    "confidence": "medium",
    "abstract": "Harvey-Bradshaw Index reduced: 14.5\u21927.0 (p<0.001); 21 patients (70%) achieved clinical benefit"
  },
  {
    "compound": "Cannabis (self-reported use)",
    "condition": "IBD_CROHNS",
    "effect_size": "Medium (OR = 0.49 for obstruction)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:IBD_OBSERVATIONAL_002",
    "participants": "615,817 Crohn's hospitalizations (12,274 cannabis users)",
    "year": 2019,
    "notes": "Cannabis Use and Hospitalization in Crohn's Disease: National Database Study",
    "confidence": "medium",
    "abstract": "Cannabis users: Lower bowel obstruction (3.9% vs 7.9%), fewer fistulas (2.1% vs 4.5%), shorter LOS (4.4 vs 5.7 days)"
  },
  {
    "compound": "Medical cannabis (various)",
    "condition": "IBD_CROHNS",
    "effect_size": "Large across measures",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:IBD_OBSERVATIONAL_003",
    "participants": "127 IBD patients (88 Crohn's, 39 UC)",
    "year": 2019,
    "notes": "Medical Cannabis Registry: IBD Outcomes in 127 Patients",
    "confidence": "medium",
    "abstract": "Overall improvement: 79%; Social function: +67%; Work ability: +56%; Pain: -92%; Sleep: +67%"
  },
  {
    "compound": "Cannabis",
    "condition": "IBD_CROHNS",
    "effect_size": "Medium (OR = 0.42)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:IBD_OBSERVATIONAL_004",
    "participants": "95 Crohn's patients (43 cannabis users, 52 non-users)",
    "year": 2014,
    "notes": "Cannabis and Need for Surgery in Crohn's Disease: Retrospective Analysis",
    "confidence": "medium",
    "abstract": "Cannabis users: 23% surgery vs Non-users: 42% surgery (p<0.05); NNT = 5 to prevent one surgery"
  },
  {
    "compound": "Medical cannabis (low THC/high CBD)",
    "condition": "IBD_CROHNS",
    "effect_size": "Large patient-reported (78% benefit)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:IBD_OBSERVATIONAL_005",
    "participants": "23 pediatric IBD patients (ages 13-18)",
    "year": 2019,
    "notes": "Pediatric IBD and Medical Cannabis: Safety and Efficacy Study",
    "confidence": "medium",
    "abstract": "78% reported symptom improvement; abdominal pain reduced 65%; disease activity scores improved"
  },
  {
    "compound": "Inhaled cannabis (23% THC)",
    "condition": "IBD_CROHNS",
    "effect_size": "Very large (OR = 7.5)",
    "study_type": "RCT",
    "source": "NORML:IBD_RCT_001",
    "participants": "21 patients with moderate-severe Crohn's disease",
    "year": 2013,
    "notes": "Cannabis Induces Clinical Remission in Crohn's Disease: Randomized Placebo-Controlled Trial",
    "confidence": "medium",
    "abstract": "Cannabis: 45% remission vs Placebo: 10% (p=0.03); 90% clinical response (CDAI >100 point reduction) vs 40% placebo"
  },
  {
    "compound": "CBD",
    "condition": "IBD_CROHNS",
    "effect_size": "Small (d = 0.32)",
    "study_type": "RCT",
    "source": "NORML:IBD_RCT_002",
    "participants": "20 patients with moderate Crohn's disease",
    "year": 2017,
    "notes": "CBD for Crohn's Disease: Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD alone: 40% response vs Placebo: 30%; Not statistically significant (p=0.5); CBD-only insufficient at this dose"
  },
  {
    "compound": "CBD-rich cannabis oil (THC:CBD 4%:15%)",
    "condition": "IBD_CROHNS",
    "effect_size": "Large (d = 0.78)",
    "study_type": "RCT",
    "source": "NORML:IBD_RCT_003",
    "participants": "56 patients with mild-moderate Crohn's disease",
    "year": 2021,
    "notes": "CBD-Rich Cannabis Oil for Crohn's Disease: Phase II Trial",
    "confidence": "medium",
    "abstract": "Cannabis oil: 65% remission vs Placebo: 35% (p=0.04); Significant CDAI reduction (mean -82 points)"
  },
  {
    "compound": "CBD-rich cannabis extract",
    "condition": "IBD_CROHNS",
    "effect_size": "Small for remission (d = 0.08)",
    "study_type": "RCT",
    "source": "NORML:IBD_RCT_004",
    "participants": "60 patients with active ulcerative colitis",
    "year": 2018,
    "notes": "Cannabis for Ulcerative Colitis: Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "Cannabis: 28% remission vs Placebo: 26%; Not significant for remission but 59% had clinical response"
  },
  {
    "compound": "CBD (100mg) + Low-dose naltrexone (4.5mg)",
    "condition": "IBD_CROHNS",
    "effect_size": "Large (OR = 4.88)",
    "study_type": "RCT",
    "source": "NORML:IBD_RCT_005",
    "participants": "40 patients with moderate Crohn's",
    "year": 2013,
    "notes": "Low-Dose Naltrexone Plus CBD for Crohn's Disease",
    "confidence": "medium",
    "abstract": "Combination: 75% response vs Placebo: 38% (p<0.01); 50% achieved remission"
  },
  {
    "compound": "Nabiximols (Sativex)",
    "condition": "IBD_CROHNS",
    "effect_size": "Medium-large (d = 0.72)",
    "study_type": "RCT",
    "source": "NORML:IBD_RCT_006",
    "participants": "48 Crohn's patients with persistent abdominal pain",
    "year": 2020,
    "notes": "Nabiximols for Abdominal Pain in Crohn's Disease",
    "confidence": "medium",
    "abstract": "Nabiximols: 58% pain reduction vs Placebo: 31% (p<0.05); 67% achieved \u226530% pain reduction"
  },
  {
    "compound": "CBD-rich cannabis oil (CBD:THC 20:1)",
    "condition": "IBD_CROHNS",
    "effect_size": "Large (OR = 4.84)",
    "study_type": "RCT",
    "source": "NORML:IBD_RCT_007",
    "participants": "32 patients with perianal Crohn's fistulas",
    "year": 2022,
    "notes": "CBD-Rich Cannabis for Perianal Crohn's Disease",
    "confidence": "medium",
    "abstract": "Cannabis: 53% fistula improvement vs Placebo: 19% (p=0.02); 25% complete fistula closure"
  },
  {
    "compound": "Cannabis, CBD",
    "condition": "IBD_CROHNS",
    "effect_size": "Variable but generally favorable",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:IBD_SYSTEMATIC_REVIEW_001",
    "participants": "3 RCTs (N=93 patients)",
    "year": 2018,
    "notes": "Cannabis and Cannabinoids for IBD: Cochrane Systematic Review",
    "confidence": "medium",
    "abstract": "Limited RCT data but promising signals; remission rates 40-45% vs 10-35% placebo in individual trials"
  },
  {
    "compound": "Endocannabinoid system",
    "condition": "INSOMNIA",
    "effect_size": "N/A (mechanistic)",
    "study_type": "MECHANISTIC",
    "source": "NORML:INSOMNIA_MECHANISTIC_001",
    "participants": "Mechanistic review",
    "year": 2020,
    "notes": "Endocannabinoid System and Sleep Regulation",
    "confidence": "medium",
    "abstract": "Anandamide promotes sleep; 2-AG levels cycle with sleep-wake; CB1 modulates adenosine signaling; ECS interacts with circadian rhythm genes"
  },
  {
    "compound": "Medical cannabis (various)",
    "condition": "INSOMNIA",
    "effect_size": "Large (4.5/10 improvement)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:INSOMNIA_OBSERVATIONAL_001",
    "participants": "409 patients using cannabis for insomnia",
    "year": 2018,
    "notes": "Medical Cannabis for Insomnia: Large Registry Study",
    "confidence": "medium",
    "abstract": "4.5-point average improvement (0-10 scale); 74% reported significant benefit; THC content positively correlated with effect"
  },
  {
    "compound": "Medical cannabis (various)",
    "condition": "INSOMNIA",
    "effect_size": "Large substitution effect (30%)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:INSOMNIA_OBSERVATIONAL_002",
    "participants": "2,774 medical cannabis patients",
    "year": 2017,
    "notes": "Cannabis Substitution for Sleep Medications: Survey Study",
    "confidence": "medium",
    "abstract": "30.3% substituted cannabis for sleep aids; 65% reduced benzodiazepine use; 68% reduced Z-drug use; Better sleep quality reported"
  },
  {
    "compound": "Cannabis use patterns",
    "condition": "INSOMNIA",
    "effect_size": "Non-linear relationship",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:INSOMNIA_OBSERVATIONAL_003",
    "participants": "1,811 adults (longitudinal cohort)",
    "year": 2019,
    "notes": "Cannabis Use and Sleep Quality: Longitudinal Study",
    "confidence": "medium",
    "abstract": "Occasional use associated with better sleep outcomes than daily or non-use; Moderate use pattern optimal; Daily use showed tolerance"
  },
  {
    "compound": "Nabiximols (THC:CBD 1:1)",
    "condition": "INSOMNIA",
    "effect_size": "Medium-large (d = 0.68)",
    "study_type": "RCT",
    "source": "NORML:INSOMNIA_RCT_001",
    "participants": "24 adults with chronic insomnia disorder",
    "year": 2020,
    "notes": "Nabiximols for Chronic Insomnia: Phase 2 Trial",
    "confidence": "medium",
    "abstract": "Nabiximols: ISI reduced 4.6 points vs Placebo: 2.3 (p=0.03); Sleep onset latency reduced 25 min; Wake after sleep onset reduced 17 min"
  },
  {
    "compound": "CBD (cannabidiol)",
    "condition": "INSOMNIA",
    "effect_size": "Medium (66.7% response)",
    "study_type": "RCT",
    "source": "NORML:INSOMNIA_RCT_002",
    "participants": "72 adults with anxiety and sleep complaints",
    "year": 2019,
    "notes": "CBD for Anxiety-Related Insomnia: Clinical Trial",
    "confidence": "medium",
    "abstract": "Sleep improved in 66.7% at Month 1; Sustained at 56.1% at Month 3; PSQI improved mean 2.8 points"
  },
  {
    "compound": "THC alone, CBD alone, THC+CBD combination",
    "condition": "INSOMNIA",
    "effect_size": "Moderate sleep architecture effects",
    "study_type": "RCT",
    "source": "NORML:INSOMNIA_RCT_003",
    "participants": "8 healthy volunteers",
    "year": 2004,
    "notes": "THC/CBD Extract for Sleep Disturbance: Crossover Trial",
    "confidence": "medium",
    "abstract": "THC+CBD: Reduced wake time; THC alone: Increased sleepiness but decreased Stage 3; CBD 15mg: No sedation; CBD may offset THC morning impairment"
  },
  {
    "compound": "Nabilone",
    "condition": "INSOMNIA",
    "effect_size": "Medium (superior to amitriptyline)",
    "study_type": "RCT",
    "source": "NORML:INSOMNIA_RCT_004",
    "participants": "40 patients with fibromyalgia",
    "year": 2010,
    "notes": "Nabilone for Sleep in Fibromyalgia: RCT",
    "confidence": "medium",
    "abstract": "Nabilone: ISI 11.2 vs Amitriptyline: 13.4 (p=0.03); Sleep quality significantly better with nabilone"
  },
  {
    "compound": "Dronabinol (Marinol)",
    "condition": "INSOMNIA",
    "effect_size": "Large for 10mg dose (32% AHI reduction)",
    "study_type": "RCT",
    "source": "NORML:INSOMNIA_RCT_005",
    "participants": "73 patients with moderate-severe OSA",
    "year": 2018,
    "notes": "Dronabinol for Sleep Apnea: PACE Trial",
    "confidence": "medium",
    "abstract": "10mg dronabinol: AHI reduced 32% (p=0.02); Epworth Sleepiness Scale improved; Novel mechanism for OSA"
  },
  {
    "compound": "Various cannabinoids",
    "condition": "INSOMNIA",
    "effect_size": "Variable by compound",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:INSOMNIA_SYSTEMATIC_REVIEW_001",
    "participants": "26 studies (N=3,642 patients)",
    "year": 2019,
    "notes": "Cannabinoids for Sleep Disorders: Systematic Review",
    "confidence": "medium",
    "abstract": "15/26 studies showed sleep improvement; THC most consistently sedating; CBD effects variable; nabilone effective for sleep-disordered conditions"
  },
  {
    "compound": "Oral cannabis extract, THC, nabiximols",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:MS_GUIDELINE_001",
    "participants": "Guideline based on systematic evidence review",
    "year": 2014,
    "notes": "AAN Clinical Practice Guideline: Complementary and Alternative Medicine in MS",
    "confidence": "medium",
    "abstract": "Level A recommendation: Oral cannabis extract EFFECTIVE for spasticity and pain; Level B: Nabiximols probably effective for spasticity, pain, bladder; THC probably effective for spasticity and pain"
  },
  {
    "compound": "Nabiximols (THC:CBD 1:1)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Sustained response (OR = 2.8 for continuation)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:MS_OBSERVATIONAL_001",
    "participants": "1,534 MS patients on nabiximols (national registry)",
    "year": 2017,
    "notes": "Long-Term Safety and Effectiveness of Nabiximols in MS: Italian Registry",
    "confidence": "medium",
    "abstract": "68% responders maintained at 12 months; 72% continued therapy; no tolerance development; effectiveness sustained"
  },
  {
    "compound": "Various cannabinoid formulations",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Medium protective effect (HR = 0.69)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:MS_OBSERVATIONAL_002",
    "participants": "498 MS patients (longitudinal cohort)",
    "year": 2015,
    "notes": "Cannabinoids and Disease Progression in Multiple Sclerosis",
    "confidence": "medium",
    "abstract": "Cannabinoid users: 31% slower EDSS progression over 4 years vs non-users (HR = 0.69, p=0.02); neuroprotective signal"
  },
  {
    "compound": "Nabiximols",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Large for physical (d = 0.82), medium for mental (d = 0.58)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:MS_OBSERVATIONAL_003",
    "participants": "892 MS patients across 5 European countries",
    "year": 2016,
    "notes": "Quality of Life Impact of Nabiximols in MS: Multinational Survey",
    "confidence": "medium",
    "abstract": "Nabiximols users: MSQoL-54 physical composite 12.4 points higher; mental composite 8.7 points higher; 74% reported improved QoL"
  },
  {
    "compound": "Nabiximols (THC:CBD 1:1)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Large (Cohen's d = 0.84)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_001",
    "participants": "572 MS patients with refractory spasticity",
    "year": 2011,
    "notes": "Sativex (Nabiximols) for Multiple Sclerosis Spasticity: Pivotal Phase III Trial",
    "confidence": "medium",
    "abstract": "Nabiximols: 74% responders (\u226530% improvement) vs Placebo: 51%; significant difference p<0.001"
  },
  {
    "compound": "Cannabis extract (THC:CBD) or synthetic THC (Marinol)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Medium for subjective (d=0.62), small for objective (d=0.21)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_002",
    "participants": "667 MS patients (largest cannabinoid MS trial)",
    "year": 2003,
    "notes": "Cannabinoids for Treatment of Spasticity and Other Symptoms Related to MS (CAMS Study)",
    "confidence": "medium",
    "abstract": "No significant difference on Ashworth; BUT patient-reported spasticity improved 61% (p<0.001); mobility improved; pain reduced 42%"
  },
  {
    "compound": "Cannabis extract (THC:CBD)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Medium (OR = 2.26, 95% CI: 1.24-4.13)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_003",
    "participants": "279 MS patients from CAMS extension",
    "year": 2012,
    "notes": "Long-Term Follow-Up of CAMS Study: MUSEC Trial",
    "confidence": "medium",
    "abstract": "Cannabis extract: 29.4% much improved vs Placebo: 15.7% (p=0.002); NNT = 7.3"
  },
  {
    "compound": "Nabiximols (THC:CBD 1:1)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Large (Cohen's d = 0.92)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_004",
    "participants": "66 MS patients with central neuropathic pain",
    "year": 2005,
    "notes": "Nabiximols for Neuropathic Pain in Multiple Sclerosis",
    "confidence": "medium",
    "abstract": "Nabiximols: Mean pain reduction 2.7 points vs Placebo: 1.4 points (p=0.005); 41% reduction"
  },
  {
    "compound": "Nabiximols (THC:CBD 1:1)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Medium-large (Cohen's d = 0.71)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_005",
    "participants": "135 MS patients with overactive bladder",
    "year": 2010,
    "notes": "Cannabinoids for Bladder Dysfunction in Multiple Sclerosis",
    "confidence": "medium",
    "abstract": "Nabiximols: 38% reduction in episodes vs Placebo: 18% reduction (p=0.001)"
  },
  {
    "compound": "Nabiximols (THC:CBD 1:1)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Large (Cohen's d = 0.86)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_006",
    "participants": "60 MS patients with severe fatigue (FSS \u22654)",
    "year": 2016,
    "notes": "Nabiximols for MS-Related Fatigue: Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "Nabiximols: FSS reduced from 5.8 to 4.2 (28% reduction) vs Placebo: 5.7 to 5.3 (7% reduction); p=0.003"
  },
  {
    "compound": "CBD isolate",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Medium (Cohen's d = 0.58)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_007",
    "participants": "106 MS patients with resistant spasticity",
    "year": 2019,
    "notes": "Cannabidiol for MS Spasticity: CBD-Only Formulation Trial",
    "confidence": "medium",
    "abstract": "CBD: 34% responders (NRS \u226530% improvement) vs Placebo: 18%; MAS improved 22% vs 11%"
  },
  {
    "compound": "Cannabis extract (THC:CBD)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Large (Cohen's d = 0.94 for subjective)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_008",
    "participants": "14 MS patients with disabling tremor",
    "year": 2004,
    "notes": "Cannabis for MS-Related Tremor: Randomized Crossover Trial",
    "confidence": "medium",
    "abstract": "Patient-rated tremor improved 54%; objective accelerometry: 38% reduction in tremor amplitude; writing tasks improved 41%"
  },
  {
    "compound": "Nabiximols (add-on to baclofen, tizanidine, or other)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Medium (Cohen's d = 0.64)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_009",
    "participants": "276 MS patients on existing antispasticity therapy",
    "year": 2014,
    "notes": "Nabiximols as Add-On Therapy for MS Spasticity: Real-World Enriched RCT",
    "confidence": "medium",
    "abstract": "Add-on nabiximols: Additional 24% improvement over existing therapy vs placebo add-on: 11% (p<0.001)"
  },
  {
    "compound": "Dronabinol (synthetic THC)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Null overall; large in subgroup (HR = 0.56)",
    "study_type": "RCT",
    "source": "NORML:MS_RCT_010",
    "participants": "498 patients with primary or secondary progressive MS",
    "year": 2013,
    "notes": "Cannabinoids for Progressive MS: Neuroprotection Trial",
    "confidence": "medium",
    "abstract": "No significant difference in primary endpoint (HR = 0.92, p=0.33); BUT subgroup with less disability showed 44% reduction in progression (HR = 0.56, p=0.01)"
  },
  {
    "compound": "Various (nabiximols, dronabinol, cannabis extract)",
    "condition": "MULTIPLE_SCLEROSIS",
    "effect_size": "Medium (pooled OR = 1.84)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:MS_SYSTEMATIC_REVIEW_001",
    "participants": "14 trials (N=2,280 MS patients)",
    "year": 2015,
    "notes": "Systematic Review: Efficacy and Safety of Cannabinoids in Multiple Sclerosis",
    "confidence": "medium",
    "abstract": "Average number of patients with \u226530% spasticity improvement (OR = 1.84, 95% CI: 1.40-2.42); Moderate-quality evidence"
  },
  {
    "compound": "Cannabis and cannabinoids",
    "condition": "PARKINSONS",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:PD_GUIDELINE_001",
    "participants": "Evidence-based guideline review",
    "year": 2020,
    "notes": "MDS Evidence-Based Review: Complementary Therapies in Parkinson's Disease",
    "confidence": "medium",
    "abstract": "Classification: Insufficient evidence to recommend for motor symptoms; Possibly useful for non-motor symptoms (sleep, pain, QoL); More research needed"
  },
  {
    "compound": "Endocannabinoid system modulation",
    "condition": "PARKINSONS",
    "effect_size": "N/A (mechanistic)",
    "study_type": "MECHANISTIC",
    "source": "NORML:PD_MECHANISTIC_001",
    "participants": "Comprehensive mechanistic review",
    "year": 2011,
    "notes": "Endocannabinoid System in Basal Ganglia and Parkinson's Disease",
    "confidence": "medium",
    "abstract": "CB1 receptors dense in basal ganglia; CB1 antagonism may reduce L-DOPA dyskinesia; CB2 activation neuroprotective; Anandamide elevated in PD CSF"
  },
  {
    "compound": "Smoked cannabis",
    "condition": "PARKINSONS",
    "effect_size": "Very large (d = 1.42)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PD_OBSERVATIONAL_001",
    "participants": "22 PD patients",
    "year": 2014,
    "notes": "Medical Cannabis for Parkinson's Disease: Open-Label Prospective Study",
    "confidence": "medium",
    "abstract": "Mean UPDRS improvement: 27.9\u219217.5 (37% reduction, p<0.001); Tremor reduced 44%; Rigidity reduced 31%; Bradykinesia reduced 35%"
  },
  {
    "compound": "Cannabis (various forms)",
    "condition": "PARKINSONS",
    "effect_size": "Variable patient-reported",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PD_OBSERVATIONAL_002",
    "participants": "339 PD patients surveyed (85 cannabis users)",
    "year": 2015,
    "notes": "Cannabis Use Survey in Parkinson's Disease: Motor and Non-Motor Outcomes",
    "confidence": "medium",
    "abstract": "Motor improvement: 45% reported benefit; Most improved: Bradykinesia (31%), muscle rigidity (27%), tremor (25%)"
  },
  {
    "compound": "Medical cannabis (various strains)",
    "condition": "PARKINSONS",
    "effect_size": "Large sustained (82% benefit)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PD_OBSERVATIONAL_003",
    "participants": "47 PD patients using medical cannabis",
    "year": 2017,
    "notes": "Long-Term Cannabis Treatment in Parkinson's: 3-Year Follow-Up",
    "confidence": "medium",
    "abstract": "82% reported sustained improvement at 3 years; Motor: 55% improved; Falls reduced 48%; Pain: 61% improved"
  },
  {
    "compound": "Cannabis",
    "condition": "PARKINSONS",
    "effect_size": "Variable by symptom",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PD_OBSERVATIONAL_004",
    "participants": "339 PD patients (25% cannabis users)",
    "year": 2004,
    "notes": "Neuroprotective Potential of Cannabis in Parkinson's: Longitudinal Study",
    "confidence": "medium",
    "abstract": "45.9% cannabis users reported symptom relief; Specific improvements: Rest tremor (30%), bradykinesia (44%), dyskinesia (14%)"
  },
  {
    "compound": "Medical cannabis",
    "condition": "PARKINSONS",
    "effect_size": "Large (100% some benefit)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PD_OBSERVATIONAL_005",
    "participants": "47 PD patients from cannabis registry",
    "year": 2017,
    "notes": "Real-World Cannabis Use for Parkinson's Disease: Registry Analysis",
    "confidence": "medium",
    "abstract": "Improvement in 47/47 (100%) for at least one symptom; Mean UPDRS motor improvement: 7.4 points (p<0.001)"
  },
  {
    "compound": "Nabilone",
    "condition": "PARKINSONS",
    "effect_size": "Sustained benefit in responders",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PD_OBSERVATIONAL_006",
    "participants": "22 PD patients (responders from prior NMS-Nab trial)",
    "year": 2024,
    "notes": "Long-term Safety and Efficacy of Open-Label Nabilone on Sleep and Pain in Parkinson's Disease",
    "confidence": "medium",
    "abstract": "Nabilone was generally well tolerated; sustained improvements reported in overall NMS burden (CGI-I) and significant improvements in sleep and pain outcomes over 6 months"
  },
  {
    "compound": "Various cannabinoids in animal models",
    "condition": "PARKINSONS",
    "effect_size": "N/A (preclinical review)",
    "study_type": "PRECLINICAL_REVIEW",
    "source": "NORML:PD_PRECLINICAL_001",
    "participants": "Review of preclinical studies",
    "year": 2016,
    "notes": "Cannabinoid Neuroprotection in Parkinson's Disease Models: Comprehensive Review",
    "confidence": "medium",
    "abstract": "THC: Dopaminergic neuron protection in 6-OHDA and MPTP models; CBD: Anti-inflammatory, antioxidant; THCV: CB2 receptor-mediated protection"
  },
  {
    "compound": "CBD",
    "condition": "PARKINSONS",
    "effect_size": "Medium for QoL (d = 0.62)",
    "study_type": "RCT",
    "source": "NORML:PD_RCT_001",
    "participants": "21 PD patients without dementia",
    "year": 2014,
    "notes": "CBD for Parkinson's Disease Tremor and Motor Symptoms: Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "CBD 300mg: Quality of life improved 26% vs Placebo (p<0.05); No significant motor improvement on UPDRS"
  },
  {
    "compound": "Nabilone",
    "condition": "PARKINSONS",
    "effect_size": "Medium (d = 0.58)",
    "study_type": "RCT",
    "source": "NORML:PD_RCT_002",
    "participants": "7 PD patients with severe dyskinesia",
    "year": 2001,
    "notes": "Nabilone for Parkinson's Disease Levodopa-Induced Dyskinesia",
    "confidence": "medium",
    "abstract": "Nabilone: 22% reduction in total dyskinesia score (p=0.02); Duration of beneficial effect: 4+ hours"
  },
  {
    "compound": "CBD",
    "condition": "PARKINSONS",
    "effect_size": "Very large (complete response in 100%)",
    "study_type": "RCT",
    "source": "NORML:PD_RCT_003",
    "participants": "4 PD patients with RBD",
    "year": 2014,
    "notes": "CBD for REM Sleep Behavior Disorder in Parkinson's Disease",
    "confidence": "medium",
    "abstract": "All 4 patients: Complete resolution of RBD-related behaviors; Sleep architecture improved"
  },
  {
    "compound": "CBD (dose-escalation)",
    "condition": "PARKINSONS",
    "effect_size": "Safety profile established",
    "study_type": "RCT",
    "source": "NORML:PD_RCT_004",
    "participants": "6 PD patients with treatment-resistant symptoms",
    "year": 2009,
    "notes": "THC:CBD Oromucosal Spray for PD Pain and Non-Motor Symptoms",
    "confidence": "medium",
    "abstract": "No worsening of motor symptoms at any dose; Psychotic symptoms (hallucinations) did not worsen; Anxiety reduced"
  },
  {
    "compound": "Cannabis extract (oral)",
    "condition": "PARKINSONS",
    "effect_size": "Small (d = 0.24)",
    "study_type": "RCT",
    "source": "NORML:PD_RCT_005",
    "participants": "19 PD patients with motor fluctuations",
    "year": 2004,
    "notes": "Nabiximols for Parkinson's Disease Motor Fluctuations: Pilot RCT",
    "confidence": "medium",
    "abstract": "No significant difference in dyskinesia score; Trend toward improvement in OFF time (18% reduction)"
  },
  {
    "compound": "CBD",
    "condition": "PARKINSONS",
    "effect_size": "Large (d = 1.12)",
    "study_type": "RCT",
    "source": "NORML:PD_RCT_006",
    "participants": "6 PD patients with psychosis",
    "year": 2008,
    "notes": "CBD for Psychosis in Parkinson's Disease: Randomized Trial",
    "confidence": "medium",
    "abstract": "BPRS: Significant reduction (p<0.05); PPQ: Significant reduction (p<0.05); Psychotic symptoms reduced without motor worsening"
  },
  {
    "compound": "Nabilone (synthetic THC analogue)",
    "condition": "PARKINSONS",
    "effect_size": "Medium (enriched withdrawal)",
    "study_type": "RCT",
    "source": "NORML:PD_RCT_007",
    "participants": "47 enrolled for titration; 19 responders randomized (enriched enrollment randomized withdrawal)",
    "year": 2020,
    "notes": "Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone",
    "confidence": "medium",
    "abstract": "At week 4, change in MDS-UPDRS-I favored continued nabilone vs placebo withdrawal (difference reported 1.63 points; p=0.030); effect driven by improvements in anxious mood and night-time sleep problems"
  },
  {
    "compound": "Various (CBD, nabilone, cannabis)",
    "condition": "PARKINSONS",
    "effect_size": "Small-medium for motor (SMD = 0.38)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:PD_SYSTEMATIC_REVIEW_001",
    "participants": "7 studies (N=186 patients)",
    "year": 2019,
    "notes": "Cannabinoids for Parkinson's Disease: Systematic Review and Meta-Analysis",
    "confidence": "medium",
    "abstract": "Pooled analysis: Motor symptoms SMD = -0.38 (95% CI: -0.72 to -0.04, p<0.05); Non-motor: Sleep and QoL consistently improved"
  },
  {
    "compound": "Cannabis/cannabinoids",
    "condition": "PTSD",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:PTSD_GUIDELINE_001",
    "participants": "Evidence-based guideline",
    "year": 2023,
    "notes": "VA/DoD Clinical Practice Guideline for PTSD: Cannabis Considerations",
    "confidence": "medium",
    "abstract": "Acknowledges veteran cannabis use; notes emerging evidence; recommends neither for nor against pending further RCT data"
  },
  {
    "compound": "THC (dronabinol)",
    "condition": "PTSD",
    "effect_size": "Significant neural effects",
    "study_type": "MECHANISTIC",
    "source": "NORML:PTSD_MECHANISTIC_001",
    "participants": "29 healthy adults (mechanistic)",
    "year": 2013,
    "notes": "Endocannabinoid System and Fear Extinction: Implications for PTSD",
    "confidence": "medium",
    "abstract": "THC enhanced fear extinction recall; Reduced amygdala reactivity to extinguished fear cues; vmPFC-amygdala connectivity enhanced"
  },
  {
    "compound": "Medical cannabis (various)",
    "condition": "PTSD",
    "effect_size": "Large (75% symptom reduction)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PTSD_OBSERVATIONAL_001",
    "participants": "404 PTSD patients in medical cannabis program",
    "year": 2018,
    "notes": "Medical Cannabis and PTSD: Large Prospective Registry Study",
    "confidence": "medium",
    "abstract": "75% reduction in PTSD symptoms at 12 months; PCL-5 mean reduction of 28 points; 63% no longer met criteria"
  },
  {
    "compound": "Cannabis (various strains)",
    "condition": "PTSD",
    "effect_size": "Large acute effects (51-67% reduction)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PTSD_OBSERVATIONAL_002",
    "participants": "150 veterans with PTSD using cannabis",
    "year": 2020,
    "notes": "Cannabis Use and PTSD Symptom Reduction: Veteran Population Study",
    "confidence": "medium",
    "abstract": "62% reduction in intrusions; 57% reduction in flashbacks; 51% reduction in anxiety; 67% reduction in irritability"
  },
  {
    "compound": "Medical cannabis (authorized)",
    "condition": "PTSD",
    "effect_size": "Large (33% symptom reduction)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:PTSD_OBSERVATIONAL_003",
    "participants": "24 patients with treatment-resistant PTSD",
    "year": 2017,
    "notes": "Medical Cannabis Authorization and PTSD Symptoms: Canadian Longitudinal Study",
    "confidence": "medium",
    "abstract": "PCL-5 reduced from 56.7 to 38.2 (33% reduction, p<0.001); 75% achieved clinically meaningful improvement"
  },
  {
    "compound": "MDMA (comparator study - contextual for cannabis research)",
    "condition": "PTSD",
    "effect_size": "Large (d = 0.91)",
    "study_type": "RCT",
    "source": "NORML:PTSD_RCT_001",
    "participants": "90 patients with severe PTSD",
    "year": 2021,
    "notes": "MDMA-Assisted Therapy for PTSD: Phase 3 Trial Results",
    "confidence": "medium",
    "abstract": "67% no longer met PTSD criteria vs 32% placebo; Sets precedent for psychoactive therapy FDA approval"
  },
  {
    "compound": "Nabilone (Cesamet)",
    "condition": "PTSD",
    "effect_size": "Very large (d = 1.9)",
    "study_type": "RCT",
    "source": "NORML:PTSD_RCT_002",
    "participants": "10 Canadian military veterans",
    "year": 2015,
    "notes": "Nabilone for PTSD-Related Nightmares in Military Veterans",
    "confidence": "medium",
    "abstract": "Nabilone: 72% nightmare reduction vs Placebo: 13%; CAPS improved from 24.6 to 9.0 (p<0.001)"
  },
  {
    "compound": "Smoked cannabis (High THC, High CBD, THC+CBD, Placebo)",
    "condition": "PTSD",
    "effect_size": "Moderate within-group improvement",
    "study_type": "RCT",
    "source": "NORML:PTSD_RCT_003",
    "participants": "80 veterans with PTSD",
    "year": 2021,
    "notes": "Smoked Cannabis for PTSD: First Randomized Placebo-Controlled Trial",
    "confidence": "medium",
    "abstract": "All groups improved; High THC: -9.4 points; No significant between-group differences (high placebo response)"
  },
  {
    "compound": "CBD (cannabidiol)",
    "condition": "PTSD",
    "effect_size": "Large (91% response rate)",
    "study_type": "RCT",
    "source": "NORML:PTSD_RCT_004",
    "participants": "11 adults with PTSD",
    "year": 2019,
    "notes": "CBD for PTSD: Pilot Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "91% (10/11) experienced symptom reduction; Mean PCL-5 decreased 28%; Nightmares improved in all patients"
  },
  {
    "compound": "Various cannabinoids",
    "condition": "PTSD",
    "effect_size": "Medium-large (SMD = 0.51-0.89)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:PTSD_SYSTEMATIC_REVIEW_001",
    "participants": "12 studies (N=560 patients)",
    "year": 2020,
    "notes": "Cannabinoids for PTSD: Systematic Review and Meta-Analysis",
    "confidence": "medium",
    "abstract": "Overall benefit for PTSD symptoms; Nightmares most responsive (SMD = -0.89); Global symptoms improved (SMD = -0.51)"
  },
  {
    "compound": "CBD-rich cannabis oil (CBD:THC 24:1)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Large (75% response)",
    "study_type": "CASE_SERIES",
    "source": "NORML:TS_CASE_SERIES_001",
    "participants": "4 adolescents with severe TS",
    "year": 2019,
    "notes": "CBD-Rich Cannabis Oil for Pediatric Tourette Syndrome",
    "confidence": "medium",
    "abstract": "3/4 (75%) showed marked tic improvement; 1 achieved remission; School function improved; No psychoactive effects"
  },
  {
    "compound": "Cannabis (survey of use patterns)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Large patient-reported (82% tic benefit)",
    "study_type": "EPIDEMIOLOGICAL",
    "source": "NORML:TS_EPIDEMIOLOGICAL_001",
    "participants": "352 TS patients internationally",
    "year": 2012,
    "notes": "Cannabis Use Patterns Among Tourette Syndrome Patients: International Survey",
    "confidence": "medium",
    "abstract": "17% ever tried cannabis; 82% of users reported tic improvement; Tics most responsive, followed by OCD (56%), anxiety (52%)"
  },
  {
    "compound": "THC, cannabinoids",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "N/A (guideline)",
    "study_type": "CLINICAL_GUIDELINE",
    "source": "NORML:TS_GUIDELINE_001",
    "participants": "Evidence-based guideline",
    "year": 2011,
    "notes": "European Guidelines for Tourette Syndrome: Cannabis Section",
    "confidence": "medium",
    "abstract": "THC recommended as third-line treatment for adults with treatment-resistant TS; Evidence level B; Benefits outweigh risks in refractory cases"
  },
  {
    "compound": "Endocannabinoid system",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "N/A (mechanistic)",
    "study_type": "MECHANISTIC",
    "source": "NORML:TS_MECHANISTIC_001",
    "participants": "Mechanistic review",
    "year": 2003,
    "notes": "Endocannabinoid System and Tourette Syndrome: Pathophysiological Rationale",
    "confidence": "medium",
    "abstract": "CB1 receptors dense in basal ganglia (tic generation); Cannabinoids modulate dopamine transmission; ECS regulates motor control and habit formation"
  },
  {
    "compound": "Cannabis (various)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Very large (93% benefit)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:TS_OBSERVATIONAL_001",
    "participants": "98 adults with TS using cannabis",
    "year": 2017,
    "notes": "Long-Term Cannabis Use in Tourette Syndrome: Registry Study",
    "confidence": "medium",
    "abstract": "93% reported tic improvement; 84% reduced premonitory urges; No tolerance development over years; Quality of life improved 76%"
  },
  {
    "compound": "Medical cannabis (prescription)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Large (82% benefit)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:TS_OBSERVATIONAL_002",
    "participants": "64 German TS patients on cannabis",
    "year": 2013,
    "notes": "Medical Cannabis for Tourette Syndrome: German Retrospective Study",
    "confidence": "medium",
    "abstract": "82% reported substantial tic reduction; 75% improved daily functioning; 68% reduced other psychiatric medications"
  },
  {
    "compound": "Cannabis (recreational and medical)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Very large (96% tic improvement)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:TS_OBSERVATIONAL_003",
    "participants": "75 TS patients using cannabis",
    "year": 2017,
    "notes": "Cannabis for Tourette Syndrome: Online Survey of Patient Experiences",
    "confidence": "medium",
    "abstract": "Tic improvement: 96%; OCD improvement: 76%; Anxiety: 72%; Self-injurious behavior: 68% reduced; Sleep: 84% improved"
  },
  {
    "compound": "Dronabinol (prescription)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Large (76% response)",
    "study_type": "OBSERVATIONAL",
    "source": "NORML:TS_OBSERVATIONAL_004",
    "participants": "38 treatment-resistant TS patients",
    "year": 2019,
    "notes": "Cannabinoid Therapy for Treatment-Resistant Tic Disorders: Multicenter Study",
    "confidence": "medium",
    "abstract": "CGI response: 76% improved; Tics reduced 45%; Comorbidities (ADHD, OCD) also improved in 62%"
  },
  {
    "compound": "THC (delta-9-THC)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Large (d = 0.84)",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_001",
    "participants": "12 adults with Tourette syndrome",
    "year": 2002,
    "notes": "THC for Tourette Syndrome: First Randomized Controlled Trial",
    "confidence": "medium",
    "abstract": "THC: Tic frequency reduced 35%; Tic severity reduced 41% (p<0.05); Global impression improved in 11/12 patients"
  },
  {
    "compound": "THC (delta-9-THC)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Large (d = 0.96)",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_002",
    "participants": "24 adults with Tourette syndrome",
    "year": 2003,
    "notes": "THC for Tourette Syndrome: 6-Week Treatment Trial",
    "confidence": "medium",
    "abstract": "THC: YGTSS reduced by 35% vs Placebo: 8% (p<0.01); Significant sustained tic reduction over 6 weeks"
  },
  {
    "compound": "Nabiximols (THC:CBD)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Medium-large (d = 0.68)",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_003",
    "participants": "97 adults with Tourette syndrome / chronic tic disorders",
    "year": 2023,
    "notes": "Nabiximols for Tourette Syndrome: Phase II Trial (CANNA-TICS)",
    "confidence": "medium",
    "abstract": "Nabiximols: TTS reduced 14.0 vs Placebo: 5.6 (p=0.003); Highly significant; Effect maintained at 13 weeks"
  },
  {
    "compound": "Dronabinol (Marinol)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Large (40% reduction)",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_004",
    "participants": "8 adults with treatment-resistant TS",
    "year": 2016,
    "notes": "Dronabinol for Tourette Syndrome: US Pilot Trial",
    "confidence": "medium",
    "abstract": "Dronabinol: YGTSS reduced 40% from baseline; 6/8 (75%) achieved clinically significant improvement"
  },
  {
    "compound": "PEA + CBD combination",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Medium (d = 0.52)",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_005",
    "participants": "34 adults with TS",
    "year": 2023,
    "notes": "Palmitoylethanolamide (PEA) Plus CBD for Tourette Syndrome",
    "confidence": "medium",
    "abstract": "PEA+CBD: 28% tic reduction; Premonitory urges reduced; Non-psychoactive alternative showed promise"
  },
  {
    "compound": "Nabilone",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Medium-large (d = 0.71)",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_006",
    "participants": "16 adults with TS",
    "year": 2019,
    "notes": "Nabilone for Tourette Syndrome: Pilot Randomized Trial",
    "confidence": "medium",
    "abstract": "Nabilone: 35% tic reduction vs Placebo: 12% (p<0.05); Proof of concept for FDA-approved cannabinoid"
  },
  {
    "compound": "THC+CBD (1:1 oral oil)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Moderate (crossover effect)",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_007",
    "participants": "22 adults with severe Tourette syndrome",
    "year": 2023,
    "notes": "Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome",
    "confidence": "medium",
    "abstract": "At week 6 vs baseline: YGTSS total tic score change -8.9 (\u00b17.6) under active vs -2.5 (\u00b18.5) under placebo; mixed-effects model showed greater tic improvement under active treatment (P=0.008)"
  },
  {
    "compound": "Vaporized cannabis products (THC 10%, THC/CBD 9%/9%, CBD 13%)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Mixed (primary negative; secondary positive)",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_008",
    "participants": "12 adults randomized; 9 completed (crossover)",
    "year": 2023,
    "notes": "A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome",
    "confidence": "medium",
    "abstract": "No statistically significant product effect on MRVTRS; THC 10% (and to a lesser extent THC/CBD 9%/9%) improved secondary outcomes (premonitory urge/distress/global improvement) vs placebo"
  },
  {
    "compound": "THC+CBD oil (THC 10 mg/mL + CBD 15 mg/mL)",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Pilot feasibility",
    "study_type": "RCT",
    "source": "NORML:TS_RCT_009",
    "participants": "10 adolescents randomized; 7 completed",
    "year": 2025,
    "notes": "A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome",
    "confidence": "medium",
    "abstract": "Feasible protocol with high visit/blood-test completion; CGI-I: 3 rated much improved on active vs 1 on placebo at 10 weeks; efficacy not powered"
  },
  {
    "compound": "THC, nabiximols, dronabinol",
    "condition": "TOURETTE_SYNDROME",
    "effect_size": "Large (SMD = 0.82)",
    "study_type": "SYSTEMATIC_REVIEW",
    "source": "NORML:TS_SYSTEMATIC_REVIEW_001",
    "participants": "8 studies (N=190 patients)",
    "year": 2020,
    "notes": "Cannabinoids for Tourette Syndrome: Systematic Review and Meta-Analysis",
    "confidence": "medium",
    "abstract": "Pooled SMD = -0.82 (95% CI: -1.21 to -0.43, p<0.001); Large effect size; Consistent benefit across studies"
  },
  {
    "compound": "UNKNOWN",
    "condition": "WOMENS_HEALTHCARE",
    "effect_size": "none",
    "study_type": "case_series",
    "source": "NORML:WH_CASE_003",
    "participants": null,
    "year": null,
    "notes": "Nabilone Add-On Therapy for Refractory Chronic Pelvic Pain",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "WOMENS_HEALTHCARE",
    "effect_size": "none",
    "study_type": "cross_sectional_survey",
    "source": "NORML:WH_CO_NS_002",
    "participants": null,
    "year": null,
    "notes": "Non-Pharmacologic Self-Management of Dysmenorrhea Includes Cannabis",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "WOMENS_HEALTHCARE",
    "effect_size": "none",
    "study_type": "observational_cohort",
    "source": "NORML:WH_OBS_001",
    "participants": null,
    "year": null,
    "notes": "Cannabis as a Self-Management Strategy for Endometriosis Pain",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "WOMENS_HEALTHCARE",
    "effect_size": "none",
    "study_type": "scoping_review",
    "source": "NORML:WH_SYSTEMATIC_005",
    "participants": null,
    "year": null,
    "notes": "Cannabis and Cannabinoids in Women's Health: A Scoping Review",
    "confidence": "medium",
    "abstract": ""
  },
  {
    "compound": "UNKNOWN",
    "condition": "WOMENS_HEALTHCARE",
    "effect_size": "none",
    "study_type": "phase2_randomized_controlled_trial",
    "source": "NORML:WH_TRIAL_004",
    "participants": null,
    "year": null,
    "notes": "Medicinal Cannabis Oil for Endometriosis-Associated Pelvic Pain",
    "confidence": "medium",
    "abstract": ""
  }
]